NZ191036A - Ether and thioether mercaptoacyl prolines and pharmaceutical compositions - Google Patents

Ether and thioether mercaptoacyl prolines and pharmaceutical compositions

Info

Publication number
NZ191036A
NZ191036A NZ191036A NZ19103679A NZ191036A NZ 191036 A NZ191036 A NZ 191036A NZ 191036 A NZ191036 A NZ 191036A NZ 19103679 A NZ19103679 A NZ 19103679A NZ 191036 A NZ191036 A NZ 191036A
Authority
NZ
New Zealand
Prior art keywords
proline
methyl
hydrogen
compound
oxopropyl
Prior art date
Application number
NZ191036A
Inventor
M A Ondetti
J Krapcho
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of NZ191036A publication Critical patent/NZ191036A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Description

<div class="application article clearfix" id="description"> <p class="printTableText" lang="en">New Zealand Paient Spedficaiion for Paient Number 1 91 036 <br><br> 1910 3 6 <br><br> Priority DaU{a): . /( J.\7? <br><br> Il.-l.~ffi <br><br> Complex Specification Filod: <br><br> c'" ' 3 r WAY 1984 <br><br> t JrliXstb - L&gt; ij. • ■••■••»•■■•■■■■■&gt; <br><br> i |» O <br><br> . w« <br><br> r.". i: <br><br> . <br><br> IH iJ lis* iiiiit/u 'i£a* i is^jf* <br><br> NEW ZEALAND <br><br> PATENTS ACT, 1953 <br><br> iU.U^* • <br><br> No.: <br><br> Date: <br><br> «&lt;V\ <br><br> COMPLETE SPECIFICATI <br><br> I* *7 JUL $979^] <br><br> ■o <br><br> Me&amp;CAl^ToAOt l^eRtwvn'fes o^T suBsTirurrD <br><br> PfiOL-t r*&gt;£s. <br><br> Xfc/We, E. R. SQUIBB &amp; SONS, INC., a corporation of Delaware having its offices at Lawrenceville-Princeton Road, Princeton, New Jersey, United Stated of America, <br><br> hereby declare the invention for which K/ we pray that a patent may be granted tojCRft/us, and the method by which it is to be performed, to be particularly described in and by the following statement:- <br><br> (followed by page la) <br><br> ■rf - "" i ^ <br><br> JA169a <br><br> 5 <br><br> 10 <br><br> 25 <br><br> MERCAPTOACYL DERIVATIVES OF SUBSTITUTED PROLINES <br><br> This invention relates to new ether and thio-ether mercaptoacyl prolines of the formula (I) <br><br> X-R <br><br> R3 R2 H C5^&gt;&lt;, <br><br> I I 'l 23 <br><br> R4- s- (CH)^ CH - CO N c — COOR <br><br> I <br><br> H <br><br> wherein the group X-R^ is located at the 3- or 4-position in the ring; <br><br> X is oxygen or sulfur; 15 R is hydrogen or lower alkyl; <br><br> R^ is lower alkyl, lower alkenyl, lower alkynyl, phenyl, substituted phenyl, phenyl-lower alkylene or substituted phenyl-lower alkylene; <br><br> R2 and R.j are independently selected from 20 hydrogen, lower alkyl, and trifluoromethyl; <br><br> R^ is hydrogen, R^-CO- or <br><br> X-R <br><br> 1 <br><br> R-j R, H_C5 . - <br><br> I I 'l <br><br> -S- (CH) CH — CO — N -C COOR <br><br> n <br><br> I <br><br> H <br><br> 191036 <br><br> -H&amp;ifeSa <br><br> -2- <br><br> R,. is lower alkyl, phenyl, or phenyl-lower alkylene; <br><br> n is 0, 1 or 2; <br><br> and salts thereof. <br><br> The invention in its broadest aspects relates to the ether and thioether raercaptoacyl prolines having formula I above, to compositions containing such compounds and to the method for using such compounds as anti-hypertensive agents. <br><br> The term lower alkyl as used in defining the symbols R, R^, R2 and R^ are straiqht or branched chain hydrocarbon radicals having from 1 to 7 carbons, for example, methyl, ethyl, propyl, isopropyl, butyl, <br><br> isobutyl, t-butyl, pentyl, isopentyl, etc.' The preferred lower alkyl groups are up to four carbons with methyl and ethyl being most preferred. <br><br> The term lower alkenyl as used in defining the symbol are mono-unsaturated straight or branched 1 to 4 carbon atom chain hydrocarbon groups having frcm 2 to 7 carbons overall such as ethenyl, propenyl, isopropenyl, butenyl, and the like. The lower alkynyl groups are straight or branched chain hydrocarbon groups of from 2 to 7 carbons having one triple bond, e.g., propargyl. <br><br> The preferred lower alkenyl groups are from 2 to 5 carbons and the preferred lower alkynyl groups are from 3 to 4 carbon atoms. <br><br> The term "lower alkylene" as used in defining the symbol are alkylene groups having from 1 to 4 carbon ator -. <br><br> The term substituted phenyl and substituted phenyl-lower alkylene as used in defining the — <br><br> 1 910 <br><br> IIA16QO- <br><br> -3 - <br><br> symbol R^ include one or two, preferably one, substitutents on the phenyl ring. Suitable substi-tuents include lower alkyl groups of 1 to 4 carbons, especially methyl, lower alkoxy groups of 1 to 4 carbons, especially methoxy, lower alkylthio groups of 1 to 4 carbons, especially methylthio, halogens, especially chloro or fluoro, trifluoromethyl, acetyloxy, and hydroxy. The hydroxy substituted phenyl and phenyl-lower alkylenes are obtained by hydrolysis of the corresponding acetyloxy substituted phenyl compound as the last step of the synthetic procedure. <br><br> The term halogen includes the four common members, i.e., chloro, bromo, fluoro, and iodo, with chloro, bromo, and fluoro being preferred. <br><br> The term phenyl-lower alkylene as used in defining the symbols R^ and R,. include groups such as (nx3 , __/7^\ wherein m is an integer from <br><br> ~(cVm\y/ <br><br> 1 to 4. Preferred phenyl-lower alkylene groups are phenylmethyl and phenylethyl, especially phenylmethyl. <br><br> The lower alkanoyl groups represented by Rt--CO- are those having the acyl radicals of the lower fatty acids, for example, acetyl, <br><br> propionyl, butyryl, isobutyryl, and the like. The lower alkanoyl groups having up to four carbons are preferred with acetyl being especially preferred. Similarly, when R,. in the group R^-CO- is phenyl-lower alkylene, benzoyl is especially preferred. <br><br> The asterisk in formula I indicates an asymmetric center which is present in the proline <br><br> ■HAl69a 1 910 <br><br> ring. Of course, an additional asymmetric center can be present in the mercapto sidechain depending upon the substituents and R^• The products of formula I accordingly exist in stereoisomeric forms or 5 as racemic mixtures thereof. All of these are within the scope of the invention. The synthesis described below can utilize the racemate or one of the enantiomers as starting materials. When the racemic starting material is used in the synthesis 10 procedure, the stereoisomers obtained in the final <br><br> „ product can be separated by conventional chromatographic or fractional crystallization methods. The X-R^ group also gives rise to cis-trans isomerism. <br><br> Preferably the asymmetric center in the 15 proline ring is in the L-configuration and if there is an asymmetric center in the mercaptoacyl sidechain it is in the D-configuration. <br><br> Preferred compounds of formula I are those wherein R is hydrogen; R^ is lower alkyl of 1 to 3 20 carbons or wherein p is zero, 1 or <br><br> -&lt;CH2&gt;^r <br><br> 6 <br><br> 2, and R^ is hydrogen, methyl, methoxy, methylthio, chloro, fluoro, trifluoromethyl or hydroxy; R^ 25 is hydrogen, methyl or trifluoromethyl; R^ <br><br> is hydrogen; n is zero or one; and R4 is hydrogen. Also preferred as intermediates are the above compounds wherein R^ is acetyl or benzoyl, especially acetyl. <br><br> 30 Most preferred are the above compounds wherein <br><br> X is oxygen; R^ is methyl or ethyl, especially <br><br> 10 <br><br> i 91 o: <br><br> -ttfdr65a~ <br><br> -5- <br><br> methyl; n is 1; R2 is hydrogen or methyl, especially methyl; R3 is hydrogen; R4 is hydrogen; and the -XR^ group is at the 4-position of the proline ring, especially wherein the -XR^^ group is in the cis configuration. <br><br> The ethers and thioethers of Formula I are obtained by coupling the ether or thioether proline of the formula (II) <br><br> H2= <br><br> xri <br><br> C COOR <br><br> * <br><br> HN <br><br> I <br><br> 15 H <br><br> Q gtS- <br><br> * • with an acid oi? iia chuiuiudl equivalent of the formula (HI) <br><br> R *2 <br><br> 20 I <br><br> R\-S-(CH) CH-COOH <br><br> 4 n wherein R*. , , „ <br><br> 4 is hydrogen or R5~CO-, to yield the product of the formula <br><br> 25 <br><br> 191036 <br><br> ilAl G 9; <br><br> -6- <br><br> (IV) <br><br> XR, <br><br> R3 R2 H2C <br><br> -x, ' <br><br> 5 -S- (CH) — CH-CO - N C . COOR . <br><br> in * <br><br> I <br><br> H <br><br> This reaction can be effected in the presence of a coupling agent like dicyclohexylcarbodiimide 10 or the like, or the acid can be activated by formation of its mixed anhydride, symmetrical anhydride, acid halide, active ester or use of Woodward reagent K, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline or the like. <br><br> 15 For a review of the methods of acylation, <br><br> see Methoden der Organishchen Chemie (Houben-Weyl), Vol. XV, part II, page 1 et seq. (1974). Preferably, the acid halide, <br><br> especially the acid chloride, of formula 20 III is reacted with the acid of formula II. <br><br> The ester compounds of formula IV, i.e., R is alkyl, can be converted to ttie free acid, i.e., R is hydrogen, by conventional means. For example, if R is t-butyl treatment with trifluoroacetic acid 25 and anisole gives the free acid. <br><br> 1 91 <br><br> o <br><br> -7- <br><br> The product of formula IV is preferably isolated and purified by crystallization, e.g., by forming the dicyclohexylamine salt and then converting the salt to the free acid form by treatment 5 with an aqueous solution of an acid, such as potassium acid sulfate. <br><br> The product of formula IV bearing the acyl group R[--CO- can be converted to the products of formula I wherein is hydrogen by conventional hydrolysis or by ammonolysis. <br><br> The products of formula I wherein R^ is <br><br> ^ XRi <br><br> R3 R2 H2C <br><br> I I | I <br><br> 15 -S- (CH) CH — CO — N C — COOH <br><br> I <br><br> H <br><br> are obtained by directly oxidizing with iodine a product of formula I wherein R^ is hydrogen. <br><br> The esters of formula I wherein R is lower 20 alkyl can be obtained from the carboxylic acid compounds, i.e., wherein R is hydrogen, by conventional esterification procedures, e.g., by esterification with a diazoalkane like diazomethane, l-alkyl-3-p-tolyltriazene, like l-n-butyl-3-p-tolyltriazene, or 25 the like. <br><br> The proline reactants of formula II can be prepared by various means. For example, a hydroxy or mercapto proline of the formula <br><br> 191036 <br><br> -8- <br><br> XH <br><br> (V) <br><br> HN C-COOH <br><br> I* <br><br> H <br><br> 5 <br><br> is acylated with an acylating agent such as acetic anhydride, acetyl chloride, propionic anhydride, butyric anhydride, benzylchloroformate, or the like, so as to protect the nitrogen. The 10 group is then introduced by reacting the N-protected form of the compound of formula V with a halide, R^-hal, wherein hal represents a halogen, preferably iodine, in the presence of silver oxide, sodium hydride, sodium hydroxide or the like, to obtain 15 the intermediate having the formula (VI) <br><br> XR, <br><br> H2C <br><br> 20 protected-N —COOR^ <br><br> H <br><br> Alkaline hydrolysis of the intermediate of formula VI with a base such as barium hydroxide, sodium hydroxide, potassium hydroxide or the like first yields the 25 free acid (COOH) and then hydrolysis with a mineral acid, such as sulfuric acid, yields the starting material of formula II. <br><br> Another method for preparing the proline reactants of formula II is by treating the N-30 protected tosyloxy proline ester, preferably the methyl <br><br> -9 - <br><br> 15 <br><br> ester of the formula (VII) <br><br> H2? <br><br> OTs protected-N C-COOalkyl <br><br> I <br><br> H <br><br> with the sodium salt of the formula <br><br> (VIII) <br><br> 10 R-^-X-Na to yield the intermediate of the formula <br><br> (IX) <br><br> H2C <br><br> XR, <br><br> protected-N — — COOalkyl <br><br> H <br><br> In formula VII the symbol Ts represents ~S0- <br><br> CH <br><br> 3 <br><br> 20 and the N-protecting group is benzyloxycarbonyl, <br><br> which is preferred, or other commonly employed acyl protecting groups. In this reaction, if the tosylate group is in the cis configuration the XR^ group will be in the trans configuration and if the tosyloxy 25 group is in the trans configuration the XR^ group will be in the cis configuration. The intermediate of formula IX is then treated to remove the alkyl ester group and is then reacted with hydrogen bromide to yield the HBr salt of the proline reactant of 30 formula II which can then be coupled with the acid, <br><br> 10 <br><br> 15 <br><br> 4IAl6 9d <br><br> -10- <br><br> preferably the acid chloride, of formula III. <br><br> The proline starting materials of formula II wherein X is sulfur and the XR^ group is attached at the 3-position of the proline can also be obtained by treating a 1,2-dehydroproline ester, preferably the t-butyl ester, of the formula (X) <br><br> N <br><br> COOalkyl with an acylating agent such as benzyl chloroformate, acetyl chloride, etc., to yield the 4,5-dehydro compound (XI) <br><br> protected-N U. COOalkyl which is then reacted with the mercaptan R^-SH to yield <br><br> S-Rl <br><br> 'COOalkyl <br><br> 20 (XII) <br><br> protected-N <br><br> wherein the -S-R^ substituent is in the trans confi-25 guration. The N-protecting and alkyl groups are then removed to yield the desired starting material. <br><br> The proline starting materials of formula II where R^ is phenyl, substituted phenyl, phenyl-lower alkylene or substituted phenyl-lower alkylene 30 can also be obtained by treating the benzyl ester <br><br> ■IIAlGOa <br><br> -11- <br><br> 1! 91036 <br><br> of the N-protected proline of formula V with the alcohol R^-OH in the presence of triphenylphosphine and diethylazodicarboxylate according to the procedure of Bittner et al., Chemistry and Industry, <br><br> 5 15 March 1975, page 281. Removal of the N-protecting group and the benzyl ester group yields the starting material of formula II. <br><br> Reference is also made to the following publications for additional illustrative information <br><br> 10 with respect to the production n of starting materials <br><br> SaeJa/vJ . ^■eci'fjc'cxho^, Acs. I S3. I 3&gt;o I t <br><br> K j p &amp; S. and intermediates:^Ondotti ot al., U.D.—Pa LfenLa <br><br> 4,040,009,—4vl05,77G, urn! 4,154,9301 Neuberger, <br><br> J. Chem. Soc. , 1945, p. 429-432; Patchett et al. , <br><br> J. Amer. Chem. Soc. 79_, p. 185-192 (1957); Baer et <br><br> 15 al. , Can. J. Biochem. and Phys., 3^7, p. 583-587 (1959); <br><br> Sheehan et al., J. Amer. Chem. Soc. 85^, p. 3863-3865 <br><br> (1963) ; Magerlein, J. Med. Chem. 10^, p. 1161-1163 <br><br> (1967). The procedures illustrated therein can be utilized as general methods for the synthesis and <br><br> 20 stereoconversion of compounds utilizable in the invention of this application. <br><br> Additional experimental details are found in the examples which are preferred embodiments and also serve as models for the preparation of other <br><br> 25 members of the group. <br><br> The compounds of this invention form basic salts with a variety of inorganic or organic bases. <br><br> The salt forming ion derived from such bases can be metal ions, e.g., aluminum, alkali metal ions, <br><br> 30 such as sodium or potassium, alkaline earth metal <br><br> t; ^ -HAirff9a~ <br><br> -12- <br><br> a 'i Q <br><br> ions such as calcium or magnesium, or an amine salt ion, of which a number are known for this purpose, for example, aralkylamines like, dibenzylamine, N,N-dibenzylethylenediamine, lower alkylamines like 5 methylamine, t-butylamine, procaine, lower alkyl- <br><br> piperidines like N-ethylpiperidine, cycloalkylamines like cyclohexylamine or dicyclohexylamine, 1-adaman-tanamine, benzathine, or salts derived from amino acids like arginine, lysine or the like. The physiologically 10 acceptable salts like the sodium or potassium salts can be used medicinally as described below and are preferred. These and other salts which are not necessarily physiologically acceptable are useful in isolating or purifying a product acceptable for the 15 purposes described below, as illustrated with the dicyclohexylamine salt and the cyclohexylamine salt in the examples. The salts are produced by reacting the acid form of the compound with an equivalent of the base supplying the desired basic ion in a medium 20 in which the salt precipitates or in aqueous medium and then lyophilizing. The free acid form can be obtained from the salt by conventional neutralization techniques, e.g., with potassium bisulfate, hydrochloric acid, etc. <br><br> 25 The compounds of this invention inhibit the conversion of the decapeptide angiotensin I to angiotensin II and therefore are useful in reducing <br><br> HA±-6-9cI— <br><br> -13- <br><br> or relieving hypertension. The compounds of this invention intervene in the renin -+ angiotensinogen •* angiotensin I angiotensin II sequence by inhibiting angiotensin converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II. Thus by administration of a hypotensively effective amount of a composition containing one or a combination of compounds of formula I or physiologically acceptable salt thereof, hypertension in the species of mammal suffering therefrom is reduced or alleviated. <br><br> A single dose, or preferably two to four divided daily doses, provided in a basis of about 0.1 to about 100 mg. per kilogram per day, preferably about 1 <br><br> to about 50 mg. per kilogram per day, is appropriate to reduce blood pressure as indicated in the animal model experiments described by S. L. Engel, <br><br> T. R. Schaeffer, M. H. Waugh and B. Rubin, <br><br> Proc. Soc. Exp. Biol. Med. 143, 483 (1973). <br><br> The substance is preferably administered orally, <br><br> but parenteral routes such as subcutaneously, <br><br> intramuscularly, intravenously or intraperitoneal]^ <br><br> can also be employed. <br><br> The compounds of this invention can be utilized to achieve the reduction of blood pressure by formulating in compositions such as tablets, capsules or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration. About 10 to about 500 mg. of a compound or mixture of compounds of formula I or physiologically acceptable salt is compounded with a physiologically acceptable vehicle, carrier, <br><br> 191036 <br><br> -mte&amp;r -14- <br><br> excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in these compositions or preparations is such that suitable dosage in the range indicated is obtained. <br><br> Illustrative of the adjuvants which may be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, <br><br> acacia, corn starch or gelatin; an excipient such as dicalcium phosphate or • microcrystalline cellulose; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry. <br><br> When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. Various other materials may b e present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both, a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor. <br><br> Sterile compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the active substance in a vehicle such as water for injection, a naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cottonseed oil, etc. <br><br> 1910 <br><br> ■IIAlGQa <br><br> -15- <br><br> The following examples are illustrative of the invention and constitute preferred embodiments. They also serve as models for the preparation of other members of the group which can be produced by replacement of the given reactants with suitably substituted analogs. All temperatures are in degrees Celsius. <br><br> -16- <br><br> •mXS 1 0 3 <br><br> Example 1 <br><br> 1-(3-Acetylthio-l-oxopropyl)-trans-4-methoxy-L-proline a) N-Acetyl-trans-4-hydroxy-L-proline <br><br> A stirred suspension of 26.2 g. (0.2 mole) of 5 trans-4-hydroxy-L-proline in 4 00 ml. of acetic acid is treated with 26 ml. of acetic anhydride. The solid gradually dissolves after 2 hours of stirring at room temperature. The solution is transferred to a 2 liter flask and the solvent is removed on a 10 rotary evaporator at a bath temperature of 45°. <br><br> The syrupy residue (57.5 g.) is diluted with 100 ml. of ether to give a crystalline solid. After cooling overnight, the solid is filtered, washed with cold ether and dried in a desiccator. This material 15 (35.7 g.) is pulverized and suspended in 100 ml. of ether, cooled and filtered to give 33.8 g. (98%) of N-acetyl-trans-4-hvdroxy-L-proline, 128~131°. Recrystallization of 0.5 g. of this material from 5 ml. of acetonitrile gives 0.45 g. of colorless 20 solid, m.p. 130-132°; [ct] -92° (c, 1% in EtOH) . <br><br> b) N-Acetyl-trans-4-methoxy-L-proline, methyl ester <br><br> A mixture of 30.0 g. (0.17 mole) of N-acetyl-trans-4-hydroxy-L-proline and 130 g. of silver oxide is pulverized in a mortar and this intimate 25 mixture is added to a 1-liter flask with 300 ml. of acetone. The slurry is stirred, treated portionwise with 130 ml. of methyl iodide and the temperature maintained below 40° by cooling with a cold water bath. After stirring for 7 hours, the mixture is 30 allowed to stand overnight. The solid is filtered, washed well with acetone and the filtrate concentrated on a rotary evaporator to give <br><br> 19103 6 <br><br> HAlGQa <br><br> -17- <br><br> 38.3 g. of syrupy residue. The latter is redissolved in 350 ml. of acetone and again treated with 130 g. <br><br> of silver oxide and 130 ml. of methyl iodide to give 41 g. of residue. The latter is distilled to yield 32.2 g. of distillate; b.p. 130-140° (0.3 mm). <br><br> After digestion in 30 ml. of cyclohexane and cooling, the nearly colorless solid N-acetyl-trans-4-methoxy-L-proline methyl ester weighs 31.4 g., m.p. 71-75°. Recrystallization from 31 ml. of ethyl acetate gives 25.1 g. (66%) of colorless solid, m.p. 76-77°. <br><br> [a]2^ -83° (c, 1% in EtOH). <br><br> c) trans-4-Methoxy-L-proline <br><br> To a stirred solution of 27.0 g. (0.085 mole) <br><br> of barium hydroxide &gt; in 525 ml. of water <br><br> (approx. 3.3 N) is added 11.0 g. (0.05 mole) of N-acetyl-trans-4-methoxy-L-proline methyl ester. <br><br> The resulting solution is stirred at 18-20° for 3 hours, cooled and treated with dilute sulfuric acid (8.8 g. of conc. in 20 ml. of water). <br><br> 10 <br><br> 20 <br><br> The acidic suspension is allowed to stand overnight. The mixture is filtered through a thick layer of Celite to give a "milky" filtrate. The latter is concentrated on a rotary evaporator at 50° using a high vacuum pump to give a milky residue weighing 25 121 g. This material is treated with dilute sulfuric acid (19.0 g. of conc. I^SO^ in 75 ml. of water) and the resulting mixture is stirred and refluxed for 3 hours. After cooling to 30°, the mixture is treated portionwise with 48 g. of barium hydroxide • <br><br> an&lt;^ t^ie then adjusted from 6.0 to 4.0 with dilute sulfuric acid. After standing overnight, the mixture is filtered through a thick layer of Celite. The "milky" filtrate is concentrated as above to <br><br> -18- <br><br> 1910 3 6 <br><br> IIAlGQa- <br><br> give 50 g. of colorless dry residue. The latter is digested with 200 ml. of hot chloroform and filtered through a bed of Celite to remove the barium sulfate. The slightly turbid filtrate is concentrated on a 5 rotary evaporator to give a gelatinous material (17.7g.), suspended in 100 ml. of ether, and filtered to give 7.5 g. (94%) of nearly colorless solid, m.p. 185-190° (dec.). This material is suspended in 30 ml. of warm acetonitrile, cooled and filtered to give 4.0 g. 10 (50%) of a colorless solid, trans-4-methoxy-L-proline, m.p. 209-211° (dec.); [ct] -75° (c, 1% in EtOH). d) 1-(3-Acetylthio-l-oxopropyl)-trans-4-methoxy-L-proline <br><br> A solution of 3.5 g. (0.024 mole) of trans-15 4-methoxy-L-proline in 50 ml. of water is stirred, <br><br> cooled to 5° and 3 g. of sodium carbonate are added. <br><br> This mixture is treated with a solution of 4.0 g. (0.024 mole) of 3-acetylthiopropionyl chloride in 5 ml. of ether during the course of 10 minutes with 20 the intermittent addition of 3 g. of sodium carbonate to maintain the pH at about 8.0. The mixture is stirred in the ice-bath for an additional hour, 25 ml. of water are added and then a solution of 5 ml. of concentrated hydrochloric acid in 25 ml. of water 25 (C02 evolution). The strongly acid solution is saturated with sodium chloride and extracted with 50 ml. of ethyl acetate (four times). The organic phases are combined, dried (MgSO^), filtered and the solvent evaporated to give 6.0 g. (90%) of 30 colorless syrupy 1-(3-acetylthio-l-oxopropyl)- <br><br> i <br><br> -HAl69a— <br><br> -19- <br><br> trans-4-methoxy-L-proline. This acid is dissolved in 25 ml. of ethyl acetate and treated with 4.7 g. <br><br> of dicyclohexylamine to give a solution which rapidly becomes a solid mass. An additional 15 ml. <br><br> 5 of ethyl acetate are added and the mixture is digested on a steam bath, cooled and filtered to give 8.7 g. <br><br> o of the dicyclohexylamine salt, m.p. 170-172 . <br><br> After crystallization from 60 ml. of acetonitrile the colorless solid weighs 8.3 g. (75%) m.p. 171-173°; 10 [a]p5 "35° (c, 1% in EtOH). <br><br> The dicyclohexylamine salt is converted to 1-(3-acetylthio-l-oxopropyl)trans-4-methoxy-L-proline by suspending 8.0 g. in 60 ml. of ethyl acetate cooled in an ice bath and treating portionwise with 60 ml. of 15 10% potassium bisulfate. The clear layers are separa ted and the aqueous portion extracted with 60 ml. of ethyl acetate (2X). The organic phases are combined, dried (MgSO^), filtered and the solvent is evaporated to give 4.6 g. (80%) of a colorless 20 syrup. <br><br> Example 2 <br><br> 1-(3-Mercapto-l-oxopropyl)-trans-4-methoxy-L-proline <br><br> To the 1-(3-acetylthio-l-oxopropyl)-trans-4-methoxy-L-proline obtained in Example 1 (4.6 g., 0.017 mole) is added a cold solution of 9 ml. of concentrated ammonia in 22 ml. of water. The base dissolves in about 30 minutes and the resulting solution (under Argon) is allowed to stand for 2 hours at room temperature. This solution is cooled, extracted with 25 ml. of ethyl acetate (2X) and the ethyl acetate extract is discarded. The solution is again layered with 25 ml. of ethyl acetate and <br><br> -20- <br><br> HA169gr acidified with 17 ml. of 1:1 hydrochloric acid. The mixture is shaken, separated and the aqueous phase extracted with 25 ml. of ethyl acetate(3X). The organic phases are combined, dried (MgSO^), filtered and the solvent removed on the rotary evaporator to give 2.3 g. (59%) of colorless syrup, 1-(3-mercapto-l-oxopropyl)-trans-4-methoxy-L-proline, toc]^ -60° (c, 1% in EtOH); 0.49 (MeOH on silica gel, visual ized with nitroprusside reagent). <br><br> Anal. Calc'd. for GgH^NC^S . 1/4H20: C, 45.46; <br><br> H, 6.57; N, 5.87; S, 13.48. <br><br> Found: C, 45.42; H, 6.78; N, 5.96; S, 13.27. <br><br> An additional 1.1 g. of product (total 3.4 g., 87%) is obtained by saturating the aqueous phase with sodium chloride and extracting with 25 ml. of ethyl acetate [2X). <br><br> The sodium salt is formed by treating the syrup with aqueous sodium bicarbonate and freeze drying. <br><br> Example 3 <br><br> (trans)-1-[D-3-(Acetylthio)-2-methy1-1-oxopropy1]-4-methoxy-L-proline <br><br> A solution of 4.3 g. (0.029 mole) of trans-4-methoxy-L-proline in 50 ml. of water is stirred, cooled to 5° and 3 g. of sodium carbonate are added. This solution is treated with 5.2 g. (0.029 mole) of D-3-(acetylthio)-2-methylpropionyl chloride in <br><br> 5 ml. of ether during the course of 10 minutes with the intermittent addition of 3 g. of sodium carbonate to maintain the pH at about 8.0. This mixture is stirred in the ice-bath for 1.5 hours, 25 ml. of water are added and then a solution of <br><br> 6 ml. of concentrated hydrochloric acid in 25 ml. of water (C02 evolution). The resulting strongly acidic solution is extracted with 50 ml. of ethyl <br><br> 191036 <br><br> -21- <br><br> acetate (four times). The organic phases are combined, dried (MgSO^), filtered and the solvent evaporated to give 6.1 g. (73%) of (trans)-l-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-4-methoxy-L-proline as a pale yellow syrupy residue. This acid is dissolved in 50 ml. of ethyl acetate and treated with a solution of 4.0 g. of dicyclohexylamine in 2 0 ml. of ethyl acetate. The product begins to crystallize from the solution in about a minute. After cooling overnight the nearly colorless solid is filtered and dried, yield 6.7 g., m.p. 175-177°; 25 o <br><br> [a]D -55 (c, 1% in EtOH) . Following crystallization from 60 ml. of acetonitrile the nearly colorless solid dicyclohexylamine salt weighs 5.6 g. (41%), m.p. 179-181°, [«]2 "62° (c, 1% in EtOH). <br><br> The dicyclohexylamine salt is converted to the acid by suspending 5.5 g. in 50 ml. of ethyl acetate, cooling in an ice-bath and treating with 50 ml. of 10% potassium bisulfate. The layers are separated and the aqueous portion is extracted with 50 ml. of ethyl acetate (2X). The organic phases are combined, dried (MgSO^), filtered and the solvent evaporated to give 3.4 g. (41%) of nearly colorless (trans)-1- [D-3-(acetylthio)-2-methyl-l-oxopropyl]-4-methoxy-L-proline as a syrup. <br><br> Example 4 <br><br> (trans)-4-Methoxy-1-(D-3-mercapto-2-methy1-1-oxopropyl)-L-proline <br><br> To (trans)-l-[D-3-(acetylthio)-2-methyl-l-oxopropyl] -4-methoxy-L-proline (3.4 g.) is added a cold solution of 8 ml. of concentrated ammonia in 20 ml. of water. The base dissolves in about 10 minutes <br><br> -22- <br><br> and the resulting solution (under Argon) is allowed to stand at room temperature for two hours. This solution is cooled, extracted with 20 ml. of ethyl acetate (2X), layered with 20 ml. of ethyl acetate and acidified with 15 ml of 1:1 hydrochloric acid. <br><br> This mixture is saturated with sodium chloride, the layers are separated and the aqueous phase is extracted with 20 ml. of ethyl acetate (3X). The organic phases are combined, dried (MgS04), filtered and the solvent evaporated to give 2.9 g. (100%) of nearly colorless <br><br> (trans)-4-methoxy-l-(D-3-mercapto-2-methyl-l-oxo- <br><br> 2 5 <br><br> propyl )-L-proline, [oc] D -80° (c, 1% in EtOH); Rj 0.53 (MeOH on silica gel, visualized with nitro-prusside reagent). <br><br> Anal, calc'd. for C-^qH^NO^S . I/4H2O: C, 47. 69; <br><br> H, 6.83; N, 5.56; S, 12.73 Found: C, 47.90; H, 6.84; N, 5.85; S, 12.76. <br><br> Example 5 <br><br> (trans)-l-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-4-ethoxy-L-proline <br><br> Utilizing the procedure described in Example 3 but substituting an equivalent quantity of trans-4-ethoxy-L-proline (J. Med. Chem., lj), 1161 (1967), for (trans)-4-methoxy-L-proline, (trans)-1-[D-3-(acetylthio) -2-methyl-l-oxopropyl]-4-ethoxy-L-proline is obtained. The product is purified as the dicyclohexylamine salt, m.p. 170-172°(crystallized_from iso-propyl alcohol); [a]^5 -64° (c, 1% in EtOH). <br><br> This salt (7.75 g.) is converted to the free acid by treating with potassium bisulfate solution as described in Example 4 to give 4.85 g. of nearly colorless (trans)-l-[D-3-(acetylthio)-2-methyl-l-oxopropyl ] -4-ethoxy-L-proline as a syrup. <br><br> &lt;f f&gt; v \ -;Z ?: <br><br> * T") <br><br> 4IA1G 9a— <br><br> -23- <br><br> Example 6 <br><br> (trans)-4-Ethoxy-l-(o-3-mercapto-2-methyl-l-oxopropyl)-L-proline <br><br> To the material from Example 5 (4.85 g.) is 5 added a cold solution of 9 ml. of concentrated ammonia in 22 ml. of water (under Argon). The mixture is treated in the same manner as Example 4 to give 4.2 g. (100%) of nearly colorless (trans)-4-ethoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L- proline as a syrup, 10 "80° (c, 1% in EtOH); 0.64 (MeOH on silica gel, visualized with nitroprusside reagent). <br><br> Anal, calc'd. for C^H^NO^S: C, 50. 55; H 7.33; <br><br> N, 5.36; S, 12.27 Found: C, 50.34; H, 7.34; N, 5.39; S, 12.11. 15 Example 7 <br><br> (cis)-l-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-4-methoxy-L-proline a) N-Carbobenzyloxy-cis-4-hydroxy-L-proline <br><br> N-Carbobenzyloxy-4-keto-L-proline (10 g. , 20 0.038) is dissolved in 300 ml. of methanol and reduced with 5.8 g. (0.15 mole) of sodium borohydride in 20 ml. of water as described in JACS, 79_, 189 (1957) to give 8.7 g. of a foamy product. This material is dissolved in 30 ml. of ethanol, treated with 3.5 g. 25 of cyclohexylamine in some ethanol, and diluted to 500 ml. with ether. On seeding and rubbing, the crystalline cyclohexylamine salt separates rapidly to give 10.8 g.; m.p. 163-165°. This cyclohexylamine salt is then treated with 30 ml. of 2N HCl and 30 extracted with ethyl acetate (4 x 50 ml.) to yield as <br><br> 1910 3 6 <br><br> 10 <br><br> HA16-93T <br><br> -24- <br><br> a glass-like material 8 g. of N-carbobenzyloxy-cis-4-hydroxy-L-proline. <br><br> b) N-Carbobenzyloxy-cis-4-methoxy-L-proline, methyl ester <br><br> N-Carbobenzyloxy-cis-4-hydroxy-L-proline (13.9 g. , 0.052 mole) is treated with 40 g. of silver oxide and 40 ml. of methyl iodide (2x) in acetone (100 ml. initially, then 120 ml.) as described in Example 1(b) to yield 17.5 g. (100%) of N-carbobenzyl-oxy-cis-4-methoxy-L-proline, methyl ester as a yellow oil. <br><br> c) N-Carbobenzyloxy-cis-4-methoxy-L-proline " ' <br><br> The N-carbobenzyloxy-cis-4-methoxy-L-proline, methyl ester (17.5 g., approximately 0.052 mole) is 15 dissolved in 135 ml. of methanol, treated dropwise at -1° to 4° with 32 ml. (0.064 mole) of 2N sodium hydroxide, then kept at 0° for one hour, and at room temperature overnight. After removing about half of the solvent on a rotary evaporator, the solution is 20 diluted with 300 ml of water, washed with ether (wash discarded), acidified while cooling with 12.5 ml. of 1:1 hydrochloric acid to pH 2, and extracted with ethyl acetate (4 x 150 ml.). The extracts are combined, dried (MgSO^), filtered and the solvent evaporated to 25 give 15 g. of an orange-yellow syrup. The latter is dissolved in 60 ml. of ethanol, treated with 6 g. of cyclohexylamine in 10 ml. of ethanol and diluted to 900 ml. with ether. On seeding and rubbing, crystalline N-carbobenzyloxy-cis-4-methoxy-L-proline, cyclohexyl-30 amine salt separates: weight after cooling overnight <br><br> 19*036 <br><br> - IIAlGQer <br><br> -25- <br><br> 10.2 g., m.p. 148-150° (s. 144°), [a]^6 "35° <br><br> (c , 1% in ethanol). Following recrystallization from 40 ml. of acetonitrile, the nearly colorless o o solid weighs 8.8 g., m.p. 150-152 (s. 145 ), 5 -34° (c, 1% in ethanol). <br><br> The cyclohexylamine salt is treated with hydrochloric acid to yield 6.9 g. (48%) of N-carbo-benzyloxy-cis-4-methoxy-L-proline as a pale yellow viscous syrup, -32° (c, 1% in ethanol). <br><br> 10 d) cis-4-Methoxy-L-proline <br><br> A mixture of 6.8 g. of N-carbobenzyloxy-cis-4-methoxy-L-proline, 210 ml. of 2:1 methanol and water, and 2.3 g. of 5% Pd-C is placed on a hydrogenator at 3 atmospheres of hydrogen for four hours. The mixture 15 is filtered to remove the catalyst and the filtrate evaporated to give 3.15 g. of a grayish solid; m.p. 218-220° (dec.). A sample is crystallized from methanol-ether to yield colorless cis-4-methoxy-L-proline, m.p. 224-226° (dec.), -42° (c, 1% in <br><br> 20 methanol). <br><br> Anal. Calc'd. for C^H^NO^: C, 49.64; H, 7,64; N, 9.65 Found: C, 49.63; H, 7.71; N, 9.54. <br><br> e) (cis)-l-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-4-methoxy-L-proline 25 cis-4-Methoxy-L-proline (3 g., 0.021 mole) and <br><br> 4.2 g. (0.023 mole) of D-3-acetylthio-2-methylpropionyl chloride in 5 ml. of ether are reacted in 60 ml. of water in the presence of sodium bicarbonate as described in Example 3. Approximately 20 ml. of 30 25% sodium carbonate (w/v) is required to bring the <br><br> 1910 <br><br> ■ IlAlGDa— <br><br> -26- <br><br> pH initially to 8.5 and to maintain it at 7.5 to 8.4 during the acylation. The resulting crude viscous product (6.4 g. ) is dissolved in 50 ml. of ethyl acetate and treated with 3.9 g. of dicyclohexylamine 5 in 20 ml. of ethyl acetate. The product crystallizes from the solution and is filtered and dried to yield 6.6 g. of dicyclohexylamine salt, m.p. 172-174° <br><br> (s. 170°), [a]^6 -60° (c, 1% in ethanol). 6.5 g. of this material is recrystal-lized from 35 ml. of 10 acetonitrile to yield 6 g. of colorless solid dicyclohexylamine salt; m.p. 173-175° (s. 170°), [&lt;*1^ -60° (c, 1% in ethanol). <br><br> Anal. Calc ' d. for C12HigNC&gt;5S • C12H23N : C, 61.24; H,9.0tX; <br><br> N , 5.95; S, 6.81 <br><br> 15 Found: C, 61,16; H, 8.81; N, 5.95; S, 6.67. <br><br> Utilizing the procedure of Example 3, the dicyclohexylamine salt is converted to the acid by suspending 5.9 g. in 60 ml. of ethyl acetate, cooling in an ice-bath and treating wich 60 ml. of 10% potassium <br><br> 20 bisulfate. The layers are separated and the aqueous phase is extracted with 50 ml. of ethyl acetato (4x). <br><br> The organic phases are combined, dried (MgSO^), <br><br> filtered and the solvent evaporated to give 3.5 g. <br><br> (60%) of colorless (cis)-1-[D-3-(acetylthio)-2- <br><br> 25 methyl-l-oxopropyl]-4-methoxy-L-proline; m.p. 90-92° <br><br> 26 <br><br> (triturated with ether), [ot] D -139 (c, 1% in ethanol), <br><br> 0.63 (methanol on silica gel). <br><br> Anal. Calc'd. for Cn _H.. rtNOcS: C, 49.81; H, 6.62; <br><br> lz iy D <br><br> N, 4.84 <br><br> 30 Found: C, 49.85; H, 6.66; N, 4.97. <br><br> 91036 <br><br> -HA169a—- <br><br> -27- <br><br> Example 8 <br><br> (cis)-4-Methoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline <br><br> The (cis)-l-[D-3-(acetylthio)-2-methyl-l-oxopropyl ] -4-methoxy-L-proline (2.9 g. , 0.01 mole) is hydrolyzed in 15 ml. water containing 6.5 ml. of concentrated ammonia as described in Example 4 to give 2.3 g. (93%) of extremely viscous (cis)-4-methoxy-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline which becoi (c, 1% in ethanol) <br><br> 10 proline which becomes waxy on standing; [a]^ -88° <br><br> Example 8a <br><br> (cis)-4-Methoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L- <br><br> proline, 1-adamantanamine salt <br><br> 15 A solution of 0.55 g. (0.0022 mole) of cis-4- <br><br> methoxy-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline in 15 ml. of ethyl acetate is treated under an atmos phere of argon with a warm solution of 0.34 g. <br><br> (0.0022 mole) of 1-adamantaneamine in 10 ml. of <br><br> 20 ethyl acetate to precipitate the salt. After three hours in the cold, the colorless solid is filtered under argon (solvent held tenaciously), washed with some cold ethyl acetate, and dried in vacuo for twenty hours to yield 0.7 g. (79%) of (cis)-4- <br><br> 25 methoxy-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline, 1-adamantanamine salt, m.p. 215-217° (s. 210°, dec. 220°), -60° (c, 1% in methanol). <br><br> HAl69a <br><br> -28- <br><br> 1910 <br><br> Example 9 <br><br> (cis)-4-Methoxy-l-(3-mercapto-2-methyl-l-oxopropyl)- <br><br> L-proline a) (cis)-4-Methoxy-l-[3-(benzoylthio)-2-methyl-5 1-oxopropyl]-L-proline <br><br> Interaction of 3-benzoylthio-2-methylpro-pionyl acid chloride (prepared by treating 3-benzoyl-thio-2-methylpropanoic acid with thionyl chloride) <br><br> with cis-4-methoxy-L-proline according to the general <br><br> 10 procedure of Example 3 yields (cis)-4-methoxy-l- <br><br> [3-(benzoylthio)-2-methyl-l-oxopropyl]-L-proline. <br><br> b) (cis)-4-Methoxy-l-(3-mercapto-2-methyl-l- <br><br> oxopropyl)-L-proline <br><br> Hydrolysis of (cis)-2-methoxy-l-[3-(benzoylthio)- <br><br> 15 2 -methyl-l-oxopropyl]-2-proline with an aqueous ammonia solution according to the general procedure of Example 4 yields (cis)-4-methoxy-l-(3-mercapto- <br><br> 2-methy1-1-oxopropyl)-L-proline. <br><br> 1 9 1 0 3 § <br><br> Hfll Ma— <br><br> -29- <br><br> Example 10 <br><br> (trans)-1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-4-propoxy-L-proline a) N-acetyl-trans-4-propoxy-L-proline, propyl ester ^ Interaction of 30 g. of N-acetyl-trans-4- <br><br> hydroxy-L-proline from Example 1(a) with 110 g. of silver oxide and 110 ml. of propyl iodide in 300 ml. <br><br> of acetone according to the procedure of Example 1(b) <br><br> gives 19.6 g. (41%) of pale yellow-orange N-acetyl-^■0 trans-4-propoxy-L-proline, propyl ester; b.p. <br><br> 155-165° (0.2 mm.). <br><br> b) N-Acetyl-trans-4-propoxy-L-proline <br><br> A solution of 6 g. (0.15 mole) of sodium hydroxide in 150 ml. of water is added to 19.4 g. <br><br> (0.075 mole) of N-acetyl-trans-4-propoxy-L-proline, <br><br> propyl ester to give a pale orange solution. After standing overnight at room temperature, the solution is extracted with 60 ml. of ethyl acetate (wash discarded), then acidified with 1:1 hydrochloric <br><br> 20 acid, then saturated with sodium chloride and extracted with 50 ml. of chloroform (3x). The organic phases are combined, dried (MgSO^), <br><br> filtered and the solvent evaporated to give 12.6 g. <br><br> of a brown oil. The latter is dissolved in 80 ml. <br><br> 25 of ethyl acetate and treated with a solution of <br><br> 10.7 g. of dicyclohexylamine in 20 ml. of ethyl acetate. The salt crystallizes at room temperature. <br><br> After standing overnight under refrigeration, the dicyclohexylamine salt is filtered and washed with <br><br> 30 cold ethyl acetate to give 17.3 g. of nearly colorless <br><br> 191036 <br><br> —HAl C9t <br><br> -30- <br><br> solid dicyclohcxylamine salt; m.p. 148-153°. Recrystal-lization of this material from 125 ml. of ethyl acetate gives 14.5 g. of colorless dicyclohexylamine salt; m.p. 157-159°, -30° (c, 1% in ethanol). <br><br> 5 Anal. Cald'd. for C1QH17N04 • C12H23N: C' 66.63; <br><br> H, 10.17; ,N, 7.07 Found: C, 66.47; H, 10.22; N, 7.06. <br><br> The dicyclohexylamine salt (14.4 g.) is converted to the free acid by pulverizing, suspending in 10 100 ml. of ethyl acetate and treating the slurry portionwise with 100 ml. of 10% potassium bisulfate. The organic phase is separated and the aqueous phase is extracted with 100 ml. of ethyl acetate (2x). The organic phases are combined, dried (MgSO^), filtered, 15 and the solvent evaporated to give 6.7 g. (41%) of N-acetyl-trans-4-propoxy-L-proline as a pale brown liquid. <br><br> c) (trans)-!-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-4-propoxy-L-proline 20 N-A^etyl-trans-4-propoxy-L-proline (6.4 g., <br><br> 0.03 mole) is treated with a solution of 10 g. of concentrated sulfuric acid in 100 ml. of water and the resulting solution is stirred and refluxed for three hours. The solution is then cooled to 15°, 25 treated portionwise with 12 g. of sodium carbonate to bring the pH to 8.0, and then treated with a solution of 5.4 g. (0.03 mole) of D-3-acetylthio-2-methylpropionyl chloride in 5 ml. of ether during 10 minutes while 7 g. of so'tiium carbonate are added 30 to maintain the pH at about 8.0. The mixture is then <br><br> V f * • <br><br> V/ «■ J' v a <br><br> 4hM09c <br><br> -31- <br><br> stirred in the ice-bath for 30 minutes and at room temperature for one hour. The product is then isolated and purified as a dicyclohexylamine salt according to the procedure of Example 3 to yield 6.3 g. <br><br> 5 of dicyclohexylamine salt; m.p. 165-167° (from aceto- <br><br> 25 o nitrile), [a] -56 (c, 1% in ethanol). <br><br> Anal. Calc1d.Dfor C,.H„.N0_S • C,C, 62.62; <br><br> 14 23 5 12 23 <br><br> H, 9.30; N, 5.61; S, 6.43 Found: C, 62.35; H, 9.48; N, 5.88; S, 6.45. <br><br> The dicyclohexylamine salt (6.1 g.) is converted to the free acid by suspending in 60 ml. of ethyl acetate, cooling in an ice-bath and treating with 60 ml. of 10% potassium bisulfate. The layers are separated and the aqueous phase is extracted with 60 ml. of 15 ethyl acetate (2x). The organic phases are combined, dried (MgSO^), filtered and the solvent evaporated to give 4.0 g. (42%) of (trans)-1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-4-propoxy-L-proline as a nearly colorless syrup. <br><br> 20 Example 11 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-trans-4-propoxy-L-proline <br><br> Hydrolysis of 4.0 g. of (trans)-1-[D-3-(acetylthio )-2-methyl-l-oxopropyl]-4-propoxy-L-proline with 25 8 ml. of concentrated ammonia in 20 ml. of water under argon according to the procedure of Example 4 gives 3.42 g. (97%) of 1-(D-3-mercapto-2-methyl-l-oxopropyl)-trans-4-propoxy-L-proline as a nearly colorless syrup, talp5 -72° (c, 1% in ethanol). <br><br> 191036 <br><br> -HAIGQq ^ <br><br> -32- <br><br> 10 <br><br> Anal. Calc'd. for C12H2N04S 1/4 H20: C' 51*49' <br><br> H, 7.74; N, 5.05; S, 11.46 Found: C, 51.66; H, 7.76; N, 5.94; S, 10.51. <br><br> Example 12 <br><br> 1-(3-Mercapto-l-oxopropyl)-cis-4-methoxy-L-proline a) 1-(3-Acetylthio-l-oxopropyl)-cis-4-methoxy-L-proline <br><br> Following the procedure of Example 1 (d), cis-4-methoxy-L-proline is treated with a solution of <br><br> 3-acetylthiopropyl chloride in the presence of sodium carbonate to yield 1-(3-acetylthio-l-oxopropyl) -cis-4-methoxy-L-proline. <br><br> b) 1-(3-Mercapto-l-oxopropyl)-cis-4-methoxy-L-proline <br><br> The 1-(3-acetylthio-l-oxopropyl)-cis-4-methoxy-15 L-proline is hydrolyzed with an aqueous solution of ammonia according to the procedure of Example 2 to yield 1-(3-mercapto-l-oxopropyl)-cis-4-methoxy-L-proline. <br><br> Example 13 <br><br> 20 (cis)-4-Ethoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline a) cis-4-Ethoxy-L-proline <br><br> Following the procedure of Example 7, parts (a) to (d) but substituting ethyl iodide for the methyl 25 iodide in part (b), one obtains (cis)-4-ethoxy-L-proline. <br><br> b) (cis)-1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]- <br><br> 4-ethoxy-L-proline <br><br> The (cis)-4-ethoxy-L-proline is reacted with a <br><br> 30 solution of D-3-acetylthio-2-methylpropionyl chloride <br><br> s V* <br><br> -33- <br><br> in the presence of sodium carbonate according to the procedure of Example 7(e) to yield (cis)-1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-4-ethoxy-L-proline. c) (cis)-4-Ethoxy-l-(D-3-mercapto-2-methyl-l-oxopro-pyl)-L-proline <br><br> The cis-1-[D-3-(acetylthio)-2-methyl-l-oxopropyl] -4-ethoxy-L-proline is hydrolyzed with a solution of aqueous ammonia according to the procedure of Example 8 to yield (cis)-4-ethoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline. <br><br> Example 14 <br><br> (trans)-4-Allyloxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline a) (trans)-4-Allyloxy-L-proline <br><br> Using the procedure of Example 1, part b, but substituting allyl bromide for methyl iodide gives the (trans)-N-acetyl-4-allyl-L-proline, allyl ester. The latter is then hydrolyzed as described in Example 1, part c, to give (trans)-4-allyloxy-L-proline. <br><br> b) (trans)-1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-4-allyloxy-L-proline <br><br> Interaction of the (trans)-4-allyloxy-L-proline from part (a) with an equivalent quantity of D-3-(acetylthio)-2-methylpropionyl chloride according to the procedure of Example 3 gives (trans)-1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-4-allyloxy-L-proline . <br><br> c) (trans)-4-Allyloxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline <br><br> The (trans)-l- [D-3-(acetylthio)—2-methyl-l- <br><br> -34- <br><br> oxopropyl]-4-allyloxy-L-proline is hydrolyzed with an aqueous ammonia solution according to the procedure of Example 4 to give (trans)-4-allyloxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline. <br><br> Example 15 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-trans-4-propargyloxy-L-proline a) (trans)-4-propargyloxy-L-proline <br><br> Using the procedure of Example 1, part b, but substituting propargyl bromide for methyl iodide gives the (trans)-N-acetyl-4-propargyl-L-proline, propargyl ester. The latter is then hydrolyzed as described in Example 1, part c, to give the (trans)-4-propargyloxy-L-proline. <br><br> b) (trans)-1-[D-3-(Acetylthio)-2-methy1-1-oxo-propyl]-4-propargyloxy-L-proline <br><br> Interaction of the (trans)-4-propargyloxy-L-proline from part &amp;) with an equivalent quantity of D-3-(acetylthio)-2-methylpropionyl chloride according to the procedure of Example 3 gives (trans)-l-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-4-propargyl-oxy-L-proline. <br><br> c) 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-trans-4-propargyloxy-L-proline <br><br> The (trans)-l-[D-3- (acetylthio)-2-methyl-l-oxopropyl]-4-propargyl-L-proline is hydrolyzed with an aqueous ammonia solution according to the procedure of Example 4 to give l-[ (D-3-mercapto-2-methyl-l-oxopropyl) ]-trans-4-propargyloxy-L-proline. <br><br> 1 9 <br><br> -HAlGQii <br><br> -35- <br><br> Example 16 <br><br> (trans)-4-Benzyloxy-l- (D-3-mercapto-2-methyl-l-oxopropyl)-L-proline a) (trans)-4-Benzyloxy-L-proline <br><br> 5 Using the procedure of Example 1, part b, <br><br> but substituting benzyl chloride for methyl iodide gives the (trans)-N-acetyl-4-benzyloxy-L-proline, benzyl ester. The latter is then hydrolyzed as described in Example 1, part c, to give the (trans)-10 4-benzyloxy-L-proline. <br><br> b) (trans)-1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-4-benzyloxy-L-proline <br><br> Interaction of the (trans)-4-benzyloxy-L-proline from part (a) with an equivalent quantity of ^5 D-3-(acetylthio)-2-methylpropionyl chloride according to the procedure of Example 3 gives (trans)-1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-4-benzyloxy-L-proline . <br><br> c) (trans)-4-Benzyloxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline <br><br> The (trans)-1-[D-3-(acetylthio)-2-methyl-1-oxopropyl]-4-benzyloxyl-L-proline is hydrolyzed with an aqueous ammonia solution according to the procedure of Example 4 to give (trans)-4-benzyloxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline. <br><br> Example 17 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-trans-4-phenethyloxy-L-proline a) (trans)-4-Phenethyloxy-L-proline <br><br> Using the method of Example 1, part b, but <br><br> 20 <br><br> 25 <br><br> '? / <br><br> 44Ai6£a^ <br><br> Q 1 0 <br><br> -36- <br><br> substituting phenethyl bromide for methyl iodide gives the (trans)-N-acetyl-4-phenethyloxy-L-proline, phenethyl ester. The latter is then hydrolyzed as described in Example 1, part c, to give the (trans)-4-phenethyloxy-L-proline. <br><br> b) (trans)-1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-4-phenethyloxy-L-proline <br><br> Interaction of the (trans)-4-phenethyloxy-L-proline from part (a) with an equivalent quantity of D-3-(acetylthio)-2-methylpropionyl chloride according to the procedure of Example 3 gives (trans)-1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-4-phenethyloxy-L-proline. <br><br> c) 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-trans-4-phenethyloxy-L-proline <br><br> The trans-1-[D-(acetylthio)-2-methyl-l-oxopropyl ]-4-phenethyloxy-L-proline is hydrolyzed with an aqueous ammonia solution according to the procedure of Example 4 to give 1-(D-3-mercapto-2-methyl-l-oxopropyl)-trans-4-phenethyloxy-L-proline. <br><br> Example 18 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-cis-3-methoxy-L-proline a) 1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-cis-3-methoxy-L-proline <br><br> Utilizing the procedure described in Example 7, but substituting an equivalent quantity of (cis)-3-methoxy-L-proline (J. Amer. Chem. Soc. 8_5, 3863 (1963)) for the (cis)-4-methoxy-L-proline, 1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-cis-3-methoxy-L- <br><br> 1910 36 <br><br> HAl6 9d <br><br> -37- <br><br> proline is obtained. <br><br> b) 1- (D-3-Mercapto-2-methyl-l-oxopropyl)-cis-3-methoxy-L-proline <br><br> The l-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-5 cis-3-methoxy-L-proline is hydrolyzed with an aqueous ammonia solution according to the procedure of Example 4 to yield 1-(D-3-mercapto-2-methyl-l-oxopropyl)-cis-3-methoxy-L-proline. <br><br> Example 19 <br><br> 10 - 1-(D,L-3-Mercapto-2-methy1-1-oxopropyl)-trans-3-methoxy-L-proline a) 1-[D,L-3-(Acetylthio)-2-methyl-l-oxopropyl]-trans-3-methoxy-L-proline <br><br> Interaction of equivalent quantities of (trans)-15 3-methoxy-L-proline (J. Amer. Chem. Soc. 8_5, 3863 (1963)) and D,L-3-(acetylthio)-2-methylpropionyl chloride according to the procedure described in Example 3 gives 1-[D,L-3-(acetylthio)-2-methyl-l-oxopropyl ]-trans-3-methoxy-L-proline. 20 b) 1- (D&gt;L-3-Mercapto-2-methyl-l-oxopropyl)-trans-3-methoxy-L-proline <br><br> The 1-[D,L-3-(acetylthio)-2-methyl-l-oxopropyl]-trans-3-methoxy-L-proline is hydrolyzed with an aqueous ammonia solution according to the procedure of 25 Example 4 to yield 1-(D,L-3-mercapto-2-methyl-l-oxopropyl)-trans-3-methoxy-L-proline. <br><br> Example 20 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-cis-4-methylthio-L-proline <br><br> 30 <br><br> HAl69d <br><br> -38- <br><br> a) 1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-cis-4-methylthio-L-proline <br><br> Interaction of equivalent quantities of cis-4-methylthio-L-proline [J. Amer. Chem. Soc., 79, 185 (1957)] and D-3-(acetylthio)-2-methylpropionyl chloride according to the procedure of Example 3 gives 1- [D-3-(acetylthio)-2-methyl-l-oxopropyl] -cis-4-methylthio-L-proline. <br><br> b) 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-cis-4-methylthio-L-proline <br><br> The 1-[D-3-( acetylthio)-2-methyl-l-oxopropyl]-cis-4-methylthio-L-proline is hydrolyzed with an aqueous ammonium solution according to the procedure of Example 4 to give 1-(D-3-mercapto-2-methyl-l-oxopropyl)-cis-4-methylthio-L-proline. <br><br> Example 21 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-trans-4-methylthio-L-proline a) 1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-trans-4-methylthio-L-proline <br><br> Interaction of equivalent quantities of trans-4-methylthio-L-proline [J. Amer. Chem. Soc., 79, 185 (1957)] and D-3-(acetylthio)-2-methylpropionyl chloride according to the procedure of Example 3 gives 1- [D-3- (acetylthio) -2-methyl-l-oxopropyl] -trans-4-methylthio-L-proline. <br><br> b) 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-trans-4-methylthio-L-proline <br><br> The 1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-trans-4-methylthio-L-proline is hydrolyzed with an <br><br> -39- <br><br> aqueous ammonia solution according to the procedure of Example 4 to give 1-(D-3-mercapto-2-methyl-l-oxopropyl)-trans-4-methylthio-L-proline. <br><br> Example 22 <br><br> 1-(D-3-Mercapto-3-methyl-l-oxopropyl)-cis-4-(4-pentenylthio)-L-proline a) (cis)-4-(4-Pentenylthio)-L-proline <br><br> Interaction of (cis)-N-acetyl-4-mercapto-L-proline [Chem. Pharm. Bull., 20[, 543 (1972)] with 5-bromo-l-pentene in acetone in the presence of silver oxide according to the procedure of Example 1, part b, gives the (cis)-N-acetyl-4-(4-pentenylthio-L-proline, 4-pentenyl ester. The latter is then hdyrolyzed as described in Example 1, part c, to give the cis-4-(4-pentenylthio)-L-proline. <br><br> b) 1-[D-3-(Acetylthio)-3-methyl-l-oxopropyl]-cis-4-(4-pentenylthio)-L-proline <br><br> Interaction of cis-4-(4-pentenylthio)-L-proline with an equivalent amount of D-3-(acetylthio)-3-methyl-propionyl chloride according to the procedure of Example 3 gives 1-[D-3-(acetylthio)-3-methyl-l-oxopropyl ]-cis-4-(4-pentenylthio)-L-proline. <br><br> c) 1-(D-3-Mercapto-3-methyl-L-oxopropyl)-cis-4-(4-pentenylthio)-L-proline <br><br> The 1-[D-3-(acetylthio)-3-methyl-l-oxopropyl]-cis-4-(4-pentenylthio)-L-proline is hydrolyzed with an aqueous ammonia solution according to tthe procedure of Example 4 to yield 1-(D-3-mercapto-3-methyl-l-oxopropyl)-cis-4-(4-pentenylthio)-L-proline. <br><br> iiaigq|i 910 <br><br> -40- <br><br> Example 23 <br><br> (trans)-1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-4-methoxy-L-proline, methyl ester <br><br> A solution of the material from Example 3 in 5 ether is treated with a slight excess of diazomethane. After standing at room temperature, the solvent is evaporated to give (trans)-1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-4-methoxy-L-proline, methyl ester. Similarly, by employing the cis material 10 from Example 7 in this procedure one obtains (cis)-1-[D-3-(acetylthio)-2-methyl-l-oxopropyl-4-methoxy-L-proline, methyl ester. <br><br> Example 24 <br><br> 1,1'-[Dithiodi-(l-D-3-mercapto-2-methyl-l-oxopropyl)]-15 bis-[(trans)-4-methoxy-L-proline] <br><br> A solution of the material from Example 4 is dissolved in ethanol, stirred and treated with a solution of one equivalent of iodine in ethanol. <br><br> The pH of the solution is maintained at 6-7 by the 20 addition of N-sodium hydroxide solution. The solvent is evaporated and the residue extracted with ethyl acetate. After drying over MgS04, the solution is filtered and the solvent is removed to give 1,11 -[dithiodi(l-D-3-mercapto-2-methyl-l-25 oxopropyl)]-bis-[(trans)-4-methoxy-L-proline]. <br><br> Similarly, by employing the cis material from Example 8 in this procedure one obtains 1,1'-[dithiodi-(l-D-3-mercapto-2-methyl-l-oxopropyl)]-bis- [ (cis)-4-methoxy-L-proline]. <br><br> 30 <br><br> 3 O 1 i <br><br> * // * <br><br> V/ <br><br> -T&gt; <br><br> HAi b ya- <br><br> -41- <br><br> Example 25 <br><br> Sodium salt of (trans)-4-methoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline <br><br> A solution of 2.5 g. of material from 5 Example 4 in 25 ml. of water is treated with 0.84 g. of sodium bicarbonate. The solution is freeze-dried to give the sodium salt of (trans)-4-methoxy-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline, Similarly, by employing the cis material 10 from Example 8 in this procedure one obtains the sodium salt of (cis)-4-methoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline. <br><br> Example 26 <br><br> 1- (4-Mercapto-1-oxobutyl)-cis-4-methoxy-L-proline 15 a) (cis)-l-(4-Acetylthio-l-oxobutyl)-4-methoxy-L-proline <br><br> Interaction of an equivalent quantity of (cis)-4-methoxy-L-proline with 4-acetylthiobutyroyl chloride according to the procedure described in 20 Example 1 gives (cis)-1-(4-acetylthio-l-oxobutyl)-4-methoxy-L-proline. <br><br> b) 1-(4-Mercapto-l-oxobutyl)-cis-4-methoxy-L-proline <br><br> Hydrolysis of (cis)-1-(4-acetylthio-l-oxobutyl)-4-methoxy-L-proline with an aqueous ammonia solution 25 according to the procedure of Example 2 yields 1- (4-mercapto-l-oxobutyl)-cis-4-methoxy-L-proline. <br><br> Example 27 <br><br> 1-(L-3-Mercapto-2-ethyl-l-oxopropyl)-trans-4-methoxy-D-proline <br><br> 30 <br><br> n <br><br> K/ <br><br> -HAlCOa- <br><br> 1 91 <br><br> -42- <br><br> a) (trans)-1-[L-(3-Acetylthio)-2-ethyl-l-oxopropyl]-4-methoxy-D-proline <br><br> Utilizing the procedure of Example 1 but substituting (trans)-4-hydroxy-D-proline for the 5 (trans)-4-hydroxy-L-proline in part (a) the (trans)-4-methoxy-D-proline is obtained. By interacting the latter compound with L- (3-acetylthio) -2-ethylpro-pionyl chloride according to the procedure of Example 3, (trans)-1-[L-(3-acetylthio)-2-ethyl-l-oxopropyl]-]_q 4-methoxy-D-proline is obtained. <br><br> b) 1-(L-3-Mercapto-2-ethyl-l-oxopropyl)-trans-4-methoxy-D-proline <br><br> Hydrolysis of (trans)-1-[L-(3-acetylthio)-2-ethyl-l-oxopropyl]-4-methoxy-D-proline with an 15 aqueous ammonia solution according to the procedure of Example 4 gives 1-(L-3-mercapto-2-ethyl-l-oxopropyl)-trans-4-methoxy-D-proline. <br><br> Example 28 <br><br> 1-(2-Mercapto-l-oxoethyl)-trans-4-methoxy-L-proline 20 a) (trans)-1-(2-Acetylthio-l-oxoethyl)-4-methoxy-L-proline <br><br> Utilizing the procedure of Example 1, but substituting 2-acetylthioacetyl chloride for the <br><br> 3-acetylthiopropionyl chloride, (trans)-1-(2-acetyl-25 thio-l-oxoethyl)-4-methoxy-L-proline is obtained. <br><br> b) 1-(2-Mercapto-l-oxoethyl)-trans-4-methoxy-L-proline <br><br> Hydrolysis of trans-1-(2-acetylthio-l-oxoethyl)- <br><br> 4-methoxy-L-proline with an aqueous ammonia solution 30 according to the procedure of Example 2 yields <br><br> 1910 <br><br> ,-HA169d— <br><br> -43- <br><br> 1-(2-mercapto-l-oxoethyl)-trans-4-methoxy-L-proline. <br><br> Example 29 <br><br> 1-(2-Mercapto-l-oxoethyl)-cis-4-methoxy-L-proline a) (cis)-1-(2-Acetylthio-l-oxoethyl)-4-methoxy-L-5 proline <br><br> Following the procedure of Example 28, cis-4-methoxy-L-proline is treated with a solution of <br><br> 2-acetylthioacetyl chloride in the presence of sodium carbonate to yield (cis)-l- (2-acetylthio-l-oxoethyl)- <br><br> 10 4-methoxy-L-proline. <br><br> b) 1-(2-Mercapto-l-oxoethyl)-cis-4-methoxy-L-proline <br><br> Hydrolysis of (cis)-1-(2-acetylthio-l-oxoethyl)-4-methoxy-L-proline with an aqueous ammonia solution yields 1-{2-mercapto-l-oxoethyl)-cis-4-methoxy-L-15 proline. <br><br> Example 30 <br><br> 1-(2-Mercapto-l-oxoethyl)-cis-4-methylthio-L-proline a) (cis)-1-(2-Acetylthio-l-oxoethyl)-4-methylthio-L-proline <br><br> 20 Interaction of equivalent quantities of <br><br> (cis)-4-methylthio-L-proline [J. Amer. Chem. Soc., 79, 185 (1957)] and 2-acetylthioacetyl chloride according to the procedure described in Example 1, yields (cis)-1-(2-acetylthio-l-oxoethyl)-4-methylthio-L-25 proline. <br><br> b) 1-(2-Mercapto-l-oxoethyl)-cis-4-methylthio-L-proline <br><br> Hydrolysis of (cis)-1-(2-acetylthio-l-oxoethyl)-4-methylthio-L-proline with an aqueous ammonia 30 solution according to the procedure of Example 2 <br><br> -44- <br><br> yields 1-(2-mercapto-l-oxoethyl)-cis-4-mcthylthio-L-proline . <br><br> Example 31 <br><br> 1-(D-3-Mercapto-3-methyl-l-oxopropyl)-cis-4-(4-5 pentynylthio)-L-proline a) (cis)-1-[D-3-(Acetylthio)-3-methyl-l-oxopropyl]-4- (4-pentynylthio)-L-proline <br><br> Interaction of (cis)-N-acetyl-4-mercapto-L-proline with 5-chloro-l-pentyne in acetone in the 10 presence of silver oxide according to the procedure of Example 1, part b, gives (cis)-N-acetyl-4-(4-pentynylthio)-L-proline, 4-pentynyl ester. The latter is then hydrolyzed as described in Example 1, part c, to give the (cis)-N-acetyl-4-(4-pentynylthio) 15 L-proline. Interaction of this compound with an equivalent quantity of D-3-(acetylthio)-3-methyl-propionyl chloride according to the procedure of Example 3 gives (cis)-1-[D-3-(acetylthio)-3-methyl-l-oxopropyl] -4- (4-pentynylthio)-L-proline. 20 b) 1-(D-3-Mercapto-3-methyl-l-oxopropyl)-cis-4-(4-pentynylthio)-L-proline <br><br> Hydrolysis of (cis)-1-[D-3-(acetylthio)-3-methyl-l-oxopropyl]-4-(4-pentynylthio)-L-proline with an aqueous ammonia solution according to the 25 procedure of Example 4 gives 1-(D-3-mercapto-3-methyl 1-oxopropyl)-cis-4-(4-pentynylthio)-L-proline. <br><br> Example 32 <br><br> (cis)-4-Benzylthio-l-(D,L-3-mercapto-3-ethyl-l-oxopropyl)-L-proline <br><br> 30 <br><br> ■ .* <br><br> /■ <br><br> ' HA109ct— <br><br> -45- <br><br> a) (cis)-1-[D,L-3-(Acetylthio)-3-ethyl-l-oxopropyl]-4-benzylthio-L-proline <br><br> Interaction of (cis)-N-acetyl-4-mercapto-L-proline with benzyl chloride in acetone in the presence of silver oxide according to the procedure of Example 1, part b, gives (cis)-N-acetyl-4-benzyl-thio-L-proline, benzyl ester. The latter is hydrolyzed as described in Example 1, part c, to give (cis)-N-acetyl-4-benzylthio-L-proline. Interaction of this compound with an equivalent amount of D,L-3-(acetylthio)valeroyl chloride according to the procedure of Example 3 gives (cis)-1-[D,L-3-(acetylthio) -3-ethyl-l-oxopropyl]-4-(benzylthio)-L-proline. <br><br> b) (cis)-4-Benzylthio-l-(D,L-3-mercapto-3-ethyl-l-oxopropyl)-L-proline <br><br> Hydrolysis of (cis)-l-[D,L-3- (acetylthio)-3-ethyl-l-oxopropyl]-4-.(benzylthio)-L-proline with an aqueous ammonia solution according to the procedure of Example 4 gives (cis)-4-benzylthio-l-(D,L-3-mercapto-3-ethyl-l-oxopropyl)-L-proline. <br><br> Example 33 <br><br> 1,1'- [Dithiodi-(l-D-3-mercapto-2-methyl-l-oxopropyl)]-bis[(trans)-4-methylthio-L-proline] <br><br> The product of Example 21 is treated with iodine in ethanol according to the procedure described in Example 24 to give 1,1'-[dithiodi-(l-D-3-mercapto-2-methyl-l-oxopropyl)]bis[(trans)-4-methylthio-L-proline] . <br><br> 1910 <br><br> MfrlOOa <br><br> -46- <br><br> Example 34 <br><br> (cis)-1-[D-3-(Benzoylthio)-2-methyl-l-oxopropyl]-4-methy1thio-L-proline <br><br> Interaction of equivalent quantities of (cis)-4-methylthio-L-proline (J. Amer. Chem. Soc., 79, 185 (1957)) and D-3-(benzoylthio)-2-methy1-propionyl chloride according to the procedure of Example 3 gives (cis)-1-[D-3-(benzoylthio)-2-methyl-l-oxopropyl ]-4-methylthio-L-proline. <br><br> Example 35 <br><br> (trans)-1-[D-3-(Phenylacetyl)-2-methyl-l-oxopropyl]-4-methylthio-L-proline <br><br> Interaction of equivalent quantities of (trans)-4-methylthio-L-proline (J. Amer. Chem. Soc., 79, 185 (1957)) and D-3-(phenylacetylthio)-2-methylpropionyl chloride according to the procedure of Example 3 gives (trans)-1-[D-3-(phenylacetyl)-2-methyl-l-oxo-propyl]-4-methylthio-L-proline. <br><br> Example 36 <br><br> (cis)-4-(4-Fluorophenoxy)-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline a) (cis)-4- (4-Fluorophenoxy)-L-proline <br><br> To a solution of 8.4 g. (0.024 mole) of N-carbobenzoxy-trans-4-hydroxy-L-proline, benzyl ester [Baer et al., Can. J. Biochem. &amp; Phys., 37_, 583 (1959)], 4.0 g. (0.036 mole) of 4-fluorophenol and 9.27 g. (0.036 mole) of triphenylphosphine in 75 ml. of dry tetrahydrofuran there is added dropwise over one hour 6.2 g. (0.036 mole) of diethylazodicarboxylate in 25 ml. of tetrahydrofuran. The solution is <br><br> 1 <br><br> HAlGQa <br><br> -47- <br><br> allowed to stir overnight at room temperature. The mixture is evaporated to dryness and 100 ml. of ether is added to the residue. A precipitate of triphenyl-phosphine and diethylazodicarboxylate is filtered off. Column chromatography (silica gel) separates out 8.1 g. of a mixture containing about 70% N-carbobenzoxy-cis-4-(4-fluorophenoxy)-L-proline, benzyl ester. <br><br> 10 ester containing mixture is hydrogenated at 1 atmosphere (room temperature) with 0.8 g. of 10% Pd/C. A white precipitate forms during the reaction. After uptake of hydrogen ceases, the mixture is filtered and the filter cake leached with three 15 125 ml. portions of hot methanol. The methanol solution is evaporated to dryness to yield 3.2 g. <br><br> o of cis-4-(4-fluorophenoxy)-L-proline; m.p. 235-236 . <br><br> 20 Found: C, 56.94; H, 5.19; N, 5.94; F, 7.97. b) 1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-cis-4- (4-fluorophenoxy)-L-proline cis-4-(4-fluorophenoxy)-L-proline in 125 ml. of 25 dry pyridine at room temperature there is added 1.0 g. (0.01 mole) of triethylamine and 2 g. (0.011 mole) of D-3-(acetylthio)-2-methylpropionyl-chloride. After stirring overnight at room temperature the mixture is evaporated to dryness. The 30 residue is taken up in water, covered with ether and <br><br> A solution of 7.5 g. of the above benzyl <br><br> Anal. Calc'd. for c11hi2FN03* 3 H2°: <br><br> C, 57.14; H, 5.48; N, 6.06; F, 8.22 <br><br> To a suspension of 2.25 g. (0.01 mole) of <br><br> 191036 <br><br> fifties <br><br> -48- <br><br> acidified with 10% hydrochloric acid. The water layer is repeatedly extracted with ether, the ether layers are combined, washed with water, dried (Na2S04) and evaporated to dryness to yield 3.9 g. of residue. <br><br> 5 The residue is chromatographed on 250 ml. of silica gel with ether to yield a fraction containing the desired product. The column is washed with methanol and the methanol washing is rechromatographed on a short silica gel column to yield more product. 10 This procedure is repeated once more to yield a total of 1.2 g. of pure 1-[D-3-(acetylthio)-2-methyl-l-oxopropyl ]-cis-4-(4-fluorophenoxy)-L-proline. c) (cis)-4-(4-Fluorophenoxy)-1-(D-3-mercapto-2-methyl-1- oxopropyl)-L-proline 15 1.2 g. of 1-[D-3-(acetylthio)-2-methyl-l- <br><br> oxopropyl ] -cis-4- (4-fluorophenoxy)-L-proline is dissolved in 25 ml. of methanol and treated with 5 ml. of concentrated ammonia under argon for 4 0 minutes. The volatiles are stripped off and the residue is 20 covered with ethyl acetate. The water layer is acidified with 10% hydrochloric acid. The layers are separated and the acid layer is washed with ethyl acetate. The combined organic layers are stripped with water (2x), saturated sodium chloride solution (2x), 25 and dried (Na^SO^). The solvent is stripped off to yield 1.1 g. of a solid foam residue of cis-4-(4-fluorophenoxy)-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline. <br><br> Anal. Calc'd. for C15HlgFN04 • 1/3 H20: 30 C, 54.05; H, 5.70; N,4.20; F, 5.70; S, 9.60 <br><br> 1910 3 6 <br><br> • IIAlGQa <br><br> -49- <br><br> Found: C, 54.04; H, 5.71; N, 4.05; F, 5.40; S, 9.61. <br><br> Thin layer chromatography showed the product at 0.30 <br><br> as detected by UV-light, SH reagent (yellow spot) <br><br> 2 5 o and vanillin (yellow spot). [«]D -80 (c, 1% in chloroform). <br><br> Example 37 <br><br> 1-(3-Mercapto-l-oxopropyl)-cis-4-phenoxy-L-proline a) (cis)-4-Phenoxy-L-proline <br><br> Following the procedure of Example 36(a) but substituting an equivalent amount of phenol for the 4-fluorophenol one obtains (cis)-4-phenoxy-L-proline. <br><br> b) 1-[3-(Acetylthio)-1-oxopropyl]-cis-4-phenoxy-L-proline <br><br> The (cis-4-phenoxy-L-proline is reacted with a solution of 3-acetylthiopropionyl chloride in the presence of sodium carbonate according to the procedure of Example 1 to yield 1-[3-(acetylthio)-1-oxopropyl]-cis-4-phenoxy-L-proline. <br><br> c) 1-(3-Mercapto-l-oxopropyl)-cis-4-phenoxy-L-proline <br><br> Hydrolysis of 1-[3-(acetylthio)-1-oxopropyl]-cis-4-phenoxy-L-proline with an aqueous ammonia solution according to the procedure of Example 2 yields 1- (3-mercapto-l-oxopropyl)-cis-4-phenoxy-L-proline. <br><br> Example 38 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-cis-4-(4-methyl-benzyloxy)-L-proline <br><br> Following the procedure of Example 36 but substituting an equivalent amount of 4-methylbenzyl <br><br> -50- <br><br> alcohol for the 4-fluorophenol in part (a) one obtains 1-(D-3-mercapto-2-methyl-l-oxopropyl)-cis-4-(4-methy1-benzyloxy)-L-proline. <br><br> Example 3 9 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-cis-4-phenethyl-oxy-L-proline <br><br> Following the procedure of Example 36 but substituting an equivalent amount of phenethyl alcohol for the 4-fluorophenol in part (a) one obtains 1-(D-3-mercapto-2-methyl-l-oxopropyl)-cis-4-phenethyl-oxy-L-proline. <br><br> Example 40 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-cis-4-(3-methyl-thiophenoxy)-L-proline <br><br> Following the procedure of Example 36 but substituting an equivalent amount of 3-methylthio-phenol for the 4-fluorophenol in part (a) one obtains 1-(D-3-mercapto-2-methyl-l-oxopropyl)-cis-4-(3-methylthiophenoxy)-L-proline. <br><br> Example 41 <br><br> (cis)-4-(4-Chlorophenoxy)-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline <br><br> Following the procedure of Example 36 but substituting an equivalent amount of 4-chlorophenol for the 4-fluorophenyl in part (a) one obtains (cis)-4-(4-chlorophenoxy)-1-(D-3-mercapto-2-methyl-l-oxopropyl )-L-proline. <br><br> Example 42 <br><br> 1-(2-Mercapto-l-oxoethyl)-cis-4-(4-methoxyphenoxy)-L-proline <br><br> -51- <br><br> HA16 9o a) (cis) - 4- (4-Methoxyphenoxy) -L-proline <br><br> Following the procedure of Example 36 (a) but substituting an equivalent amount of 4-methoxy-phenol for the 4-fluorophenol one obtains (cis)-4-(4-methoxyphenoxy)-L-proline. <br><br> b) 1-[2-(Acetylthio)-1-oxoethyl]-cis-4-(4-methoxyphenoxy) -L-proline <br><br> The (cis)-4-(4-methoxyphenoxy)-L-proline is reacted with a solution of 2-acetylthioacetyl chloride according to the procedure of Example 1, part (d) , to yield 1- [2-(acetylthio)-1-oxoethyl]-cis-4-£4-^methoxyphenoxy)-L-proline. <br><br> c) 1-(2-Mercapto-l-oxoethyl)-cis-4-(4-methoxyphenoxy)-L-proline <br><br> Hydrolysis of 1-[2-(acetylthio)-1-oxoethyl]-cis-4-(4-methoxyphenoxy)-L-proline with an aqueous ammonia solution according to the procedure of Example 2 yields 1-(2-mercapto-l-oxoethyl)-cis-4-(4-methoxyphenoxy)-L-proline. <br><br> Example 4 3 <br><br> (cis)-4-(4-Fluorophenylthio)-1-(D-3-mercapto-2-methy1-1-oxopropyl)-L-proline <br><br> Following the procedure of Example 36 but substituting an equivalent amount of 4-fluorophenyl-mercaptan for the 4-fluorophenol in part (a) one obtains (cis)-4-(4-fluorophenylthio)-1-(D-3-mercapto-2-methyl-l-oxopropy1)-L-proline. <br><br> 191036 <br><br> rHA1gQ"- <br><br> -52- <br><br> Example 44 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-cis-4-phenyl-thio-L-proline a) N-Carbobenzyloxy-cis-4-phenylthio-L-proline, 5 methyl ester <br><br> Sodium metal (0.85 g. , 0.037 mole) is dissolved in 40 ml. of absolute ethanol. To this there is added with stirring 3.7 ml. (0.036 mole) of thiophenol followed by 7.5 g. (0.017 mole) of N-carbobenzyloxy-10 trans-4-tosyloxy-L-proline, methyl ester [J. Am. <br><br> Chem. Soc., 7J), 191 (1957)]. The latter gradually goes into solution but soon thereafter a solid product separates. After stirring for 4 hours and standing overnight at room temperature, the bulk 15 of the ethanol is removed on a rotary evaporator. <br><br> The mostly solid residue is stirred with 120 ml. of dichloromethane and 60 ml. of water. The layers are separated (some methanol is added to help break up emulsions) and the aqueous phase is extracted with 20 additional dichloromethane ( 2 x 60 ml.). The combined organic phase are washed with 100 ml. of saturated sodium chloride solution, dried (MgSO^), and the solvent evaporated to give 6.5 g. (100%) of N-carbobenzyloxy-cis-4-phenylthio-L-proline, methyl 25 ester as a pale yellow viscous oil. <br><br> b) N-Carbobenzyloxy-cis-4-phenylthio-L-proline <br><br> The methyl ester product from part (a) (6.5 g., 0.017 mole) is dissolved in 55 ml. of methanol, treated portionwise at -1° to 4° with 30 13 ml. (0.026 mole) of 2N sodium hydroxide, stirred <br><br> 191036 <br><br> JiAlC Oer <br><br> -53- <br><br> at 0° for one hour, and kept at room temperature for approximately 16 hours. After removing about half of the solvent on a rotary evaporator, the cooled solution is diluted with 100 ml. of water, washed with 5 60 ml. of ether (wash discarded), layered over with 7 0 ml. of ethyl acetate, stirred, cooled, and acidified with 4.8 ml. of 1:1 hydrochloric acid. After separating, the aqueous phase is extracted with additional ethyl acetate (3 x 40 ml.) and the 10 combined organic layers are dried (MgSO^) and evaporated to give 5.9 g. of a light yellow viscous oil. The latter is dissolved in 30 ml. of" ( ethanol, treated with 1.9 g. of cyclohexylamine in 3 ml. of ethanol. and diluted to 330 ml. with ether. 15 On seeding,, the crystalline cyclohexylamine salt separates. The latter, after cooling for approximately 16 hours, weighs 5.3 g.; m.p. 148-151° <br><br> (s. 135°). This material is combined with 1.5 g. of identical product from a previous experiment, stirred 20 with 200 ml. of boiling acetonitrile, and cooled to yield 6.3 g. of colorless cylcohexylamine salt; m.p. 152-155° (s. 137°) [a]26 -24° (c, 1% in ethanol). <br><br> This cyclohexylamine salt is suspended in 25 ml. of ethyl acetate, stirred, and treated with 25 ml. of 25 N hydrochloric acid. When two clear layers are obtained, they are separated and the aqueous phase is extracted with additional ethyl acetate ( 3 x 25 ml.). The combined organic layers are dried (MgSO^) and the solvent evaporated to give 5.0 g. (65%) of N-carbo-30 benzyloxy-cis-4-phenylthio-L-proline as a nearly <br><br> 1910 <br><br> -54- <br><br> colorless, very viscous syrup. <br><br> c) (cis)-4-Phenylthio-L-proline hydrobromide <br><br> N-Carbobenzyloxy-cis-4-phenylthio-L-proline (4.9 g., 0.014 mole) is treated with 25 ml. of hydrogen bromide in acetic acid (30-32%), stoppered loosely, 5 and stirred magnetically. After one hour the orange-yellow solution is diluted to 250 ml. with ether to precipitate the product as a heavy oil which gradually crystallizes on seeding, rubbing and cooling. After stirring in an ice-bath for one hour, the material 10 is filtered under nitrogen, washed with ether, <br><br> -suspended in fresh ether, cooled for approximately 16 hours, and filtered again to give 3.2 g. (77%) of colorless solid (cis)-4-phenylthio-L-proline hydrobromide; m.p. 106-109° (s. 99°), [cc i ^ ^ -3° 15 (c, 1% in methanol). <br><br> d) 1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl]-cis-4-phenylthio-L-proline <br><br> Interaction of 3.0 g. (0.0094 mole) of (cis)-4-phenylthio-L-proline hydrobromide and 2.0 g. (0.011 20 mole) of D-3-acetylthio-2-methylpropionyl chloride in 25 ml. of water as described in Example 1, part (d) (using approximately 15 ml. of 20% soduim carbonate solution to maintain the pH at 8.0 to 8.4), yields 3.8 g. of a pale yellow viscous oil. The dicyclohexyl-2 5 amine salt (prepared in 30 ml. of ethyl acetate employing 1.8 g. of dicyclohexylamine) weighs 2.9 g. (isolated in two crops); m.p. 184-188° (s. 180°). Following trituration with 15 ml. of acetonitrile, one obtains 2.4 g. of colorless solid dicyclohexyl-30 amine salt; m.p. 184-186° (s. 180°), -75° <br><br> 1 91 <br><br> rs <br><br> ,-IIAlOQ i&gt; <br><br> -55- <br><br> (c, 1% in ethanol). <br><br> This dicyclohexylamine salt is treated with 30 ml. of 10% potassium bisulfate and extracted into ethyl acetate as described in Example 1 to yield 5 2.0 g. (59%) of glass-like 1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-cis-4-phenylthio-L-proline. e) 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-cis-4-phenylthio-L-proline <br><br> The 1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-10 cis-4-phenylthio-L-proline (2.0 g., 0.0042 mole) is treated with 3.5 ml. of concentrated ammonia in 8.5 ml. of water according to the procedure of Example 2 (the solid ammonium salt of the product separates from the reaction mixture) to give 1.35 g. 15 (100%) of viscous syrupy 1-(D-3-mercapto-2-methyl-1-oxopropyl)-cis-4-phenylthio-L-proline, [a]^ -43° (c, 1% in ethanol). <br><br> Example 45 <br><br> 1-(D-3-Mercapto-2-methyl-l-oxopropyl)-cis-4-(4-20 chlorophenylthio)-L-proline <br><br> Following the procedure of Example 44 but substituting an equivalent amount of 4-chlorophenyl-mercaptan for the thiophenol in part (a) one obtains 1-(D-3-mercapto-2-methyl-l-oxopropyl)-cis-4-(4-chloro-25 phenylthio)-L-proline. <br><br> Example 4 6 <br><br> 1- (D-3-Mercapto-2-methyl-l-oxopropyl)-cis-4-(3-trifluoromethylphenylthio)-L-proline <br><br> Following the procedure of Example 44 but 30 substituting an equivalent amount of 3-trifluoro- <br><br> - 56- <br><br> 1 *3 1 0 <br><br> fHAl b 9d. <br><br> methylphenylmercaptan for the thiophenol in part (a) one obtains 1-(D-3-mercapto-2-methyl-l-oxopropyl-cis-(3-trifluoromethylphenylthio)-L-proline. <br><br> Example 4 7 <br><br> (cis)-4-(4-Hydroxyphenylthio)-1-(3-mercapto-l-oxopropyl)-L-proline a) (cis)-4-(4-Acetyloxyphenylthio)-L-proline hydrobromide <br><br> Following the procedure of Example 44 (a) to (c) but substituting an equivalent amount of 4-acetyloxy-phenylmercaptan for the thiophenol in part (a) one obtains (cis)-4-(4-acetyloxyphenylthio)-L-proline hydrobromide. <br><br> b) (cis)-4-(4-Acetyloxyphenylthio)-1-[3-(acetylthio)-1-oxopropyl1-L-proline <br><br> Interaction of (cis)-4-(4-acetyloxyphenylthio)-L-proline hydrobromide and 3-acetylthiopropionyl chloride according to the procedure described in Example 1, part (d) yields (cis)-4-(4-acetyloxyphenylthio) -1-[3-acetylthio)-1-oxopropyl]-L-proline. <br><br> c) (cis)-4-(4-Hydroxyphenylthio)-1-(3-mercapto-l-oxopropy1)-L-proline <br><br> Hydrolysis of (cis)-4-(4-acetyloxyphenylthio)-1-[3-(acetylthio)-1-oxopropyl]-L-proline with an aqueous ammonia solution according to the procedure of Example 2 yields (cis)-4-(4-hydroxyphenylthio)-1-(3-mercapto-l-oxopropyl)-L-proline. <br><br> 9 <br><br> -57- <br><br> Example 4 8 <br><br> (cis)-4-Denzyloxy-1-(D-3-mercapto-2-methyl-l-oxopropyl )-L-proline <br><br> Following the procedure of Example 4 4 but 5 substituting an equivalent amount of benzyl alcohol for the thiophenol in part (a) one obtains (cis)-4-benzyloxy-l-(D-3-mercapto-2-ethyl-l-oxopropyl)-L-proline. <br><br> Example 4 9 <br><br> 10 (trans)-1-(3-Mercapto-l-oxopropyl)-3-methylthio-D,L-proline a) 1,2-Dehydroproline, t-butyl ester <br><br> To a stirred solution of 34.2 g. (0.20 mole) of proline t-butyl ester in 600 ml. of ether at -5° 15 to 0° is added dropwise over ten minutes 21.7 g. <br><br> (23.9 ml. , 0.20 mole) of freshly prepared t-butyl hypochlorite [Org. Syn., Coll. Vol. V, 184 (1973)]. During the addition, the temperature is maintained at -5°to 0°. After the addition is complete, the 20 solution is stirred at this temperature for an additional five minutes. <br><br> To the vigorously stirred solution is added rapidly 3-5 min.) a solution of 7.8 g. (0.20 mole) of potassium in freshly distilled dry (CaH^) t-.butanol 25 After the addition, the temperature of the reaction mixture is about 18°. The reaction vessel is removed from the cooling bath and stirred for thirty minutes. The reaction mixture is filtered through Celite (diatomaceous earth) and the filtrate concentrated in 30 vacuo. The residue is taken up in ether and washed <br><br> 58- <br><br> _JL£ 1 0 <br><br> with several portions of water. The ether solution is dried and concentrated in vacuo to 31.6 g. of yellow liquid. A trace of hydroquinone is added and the crude product distilled, affording 22.4 g. <br><br> 5 of 1,2-dehydroproline, t-butyl ester (66%), b.p. 60-62°/0.1 mm. <br><br> b) l-Benzyloxycarbonyl-4,5-dihydro-lH-pyrrole-2-carboxylic acid, t-butyl ester <br><br> A solution of 16.9 g. (0.1 mole) of 1,2-dehydro-10 proline, t-butyl ester in 70 ml. of dichloromethane is cooled to -10° under argon. A solution of freshly distilled benzylchloroformate (14.2 ml., 0.1 mole, b.p. 62-64° (0.4 mm)) in 70 ml. of dichloromethane is added dropwise over a period of 30 minutes. After 15 stirring in the cold for another 30 minutes a solution of 15.22 g. (0.1 mole) of 1,5-diazabicyclo-[5.4.0]undec-5-ene in 70 ml. of dichloromethane is added over a period of 20 minutes. The cooling bath is then removed and the mixture is stirred at room 20 temperature for one hour. After washing twice with cold dilute hydrochloric acid and once with saturated sodium carbonate solution, the solution is dried in vacuo to yield 18.2 g. (60%) of 1-benzyloxycarbonyl-4,5-dihydro-lH-pyrrole-2-carboxylic acid, t-butyl 25 ester as a pale yellow oil. <br><br> c) (trans)-l-Benzyloxycarbonyl-3-methylthio-D,L-proline, t-butyl ester <br><br> A solution of 18.2 g. (0.06 mole) of 1-benzyl-oxycarbonyl-4,5-dihydro-lH-pyrrole-2-carboxylic acid, 30 t-butyl ester in 180 ml. of dry methanol is treated <br><br> 1910 <br><br> - IIAlGQa <br><br> "5 9- <br><br> with 3.24 g. (0.06 mole) of sodium methoxide and cooled in an ice-bath. Methanethiolis bubbled into the solution slowly for 30 minutes. The mixture is stirred overnight under argon at room temperature. <br><br> Dilute aqueous acetic acid is added until the solution is slightly acidic. Argon is bubbled through the solution for one hour before it is taken to near dryness in vacuo. Ethyl acetate is added and the solution is washed twice with saturated sodium carbonate solution, dried and freed of solvent in vacuo to yield 17 g. of yellow oil. This oil is chromato-graphed using 300 g. of silica gel and petroleum ether: ether (4:1) to yield 11.1 g. of (trans)-1-benzyl-oxycarbonyl-3-methylthio-D,L-proline as a colorless oil. d) (trans)-3-Methylthio-D,L-proline <br><br> 8.4 g. (0.024 mole) of (trans)-1-benzyloxy-carbonyl-3-methylthio-D,L-proline are treated with 4 5 ml. of 4N hydrobromic acid in acetic acid. <br><br> After stirring for one hour at room temperature the solution is dried in vacuo. A small amount of water is added and this is washed twice with ether. The aqueous solution is applied to a column containing 300 ml. of an ion-exchange resin and water is passed through until the eluate is no longer strongly acidic. The product is then eluted with pH 6.5 (aqueous pyridine acetate) buffer. Fractions positive to nin-hydrin are combined and lyophilized to give 3.4 g. (88%) of white fluff. A small sample of this material is crystallized from methanol to give (trans)-3-methylthio-D,L-proline; m.p. 196-200° (dec.) (s. 192°). <br><br> 1 91 <br><br> -60- <br><br> Anal. Calc'd. for CgH^^O^NS: C, 44.70; H, 6.88; <br><br> N, 8.69; S, 19.89 Found: C, 44.53; H, 7.10; N, 8.61; S, 19.95. e) (trans)-1-[3-(Acetylthio)-1-oxopropyl]-3-methyl-thio-D,L-proline <br><br> 3.05 g. (0.019 mole) of (trans)-3-methylthio-D,L-proline is dissolved in 19 ml. of IN sodium carbonate and diluted with 10 ml. of water. The solution is cooled in an ice-bath and while stirring rapidly a solution of 3-acetylthiopropionyl chloride in 20 ml. of ether is added. The pH is maintained at 8 by adding IN sodium carbonate. At the end of 30 minutes the pH is holding constant and 45 ml. of sodium carbonate solution had been added. The layers are separated and the aqueous layer is washed once with ether. The aqueous layer is then acidified with 10% potassium bisulfate solution and the product is extracted into ethyl acetate, dried and freed of solvent in vacuo to give 5.2 g. of oil. The material is chromatographed on 150 g. silica gel using ethyl acetate for elution. 3.85 g. of somewhat crude (trans)-1-[3-(acetylthio)-1-oxopropyl]-3-methylthio-D,L-proline are obtained. <br><br> A small sample is dissolved in ether and converted to the dicyclohexylamine salt which is the recrystallized from ethyl acetate to give (trans)-l-[3-(acetylthio)-1-oxopropyl]-3-methylthio-D,L-proline, dicyclohexylamine salt; m.p. 153-157°. <br><br> 1 910 3 <br><br> -61- <br><br> Anal. Calc'd. for ciiHi704NS * ^C6H11^2NH: <br><br> C, 58.44; H, 8.53; N, 5.83; S, 13.57 Found: C, 58.77; H, 8.57; N, 5.68; S, 13.74. <br><br> f) (trans)-l- (3-Mercapto-l-oxopropyl) —3-methylthio-5 D,L-proline <br><br> 2.05 g. (0.007 mole) of (trans)-l-[3-(acetylthio) -1-oxopropyl]-3-methylthio-D,L-proline is cooled in an ice-bath under argon and treated with a cold argon saturated mixture of 7 ml. of water and 10 7 ml. of concentrated ammonia. After stirring for 30 minutes at 0° the solution is acidified with hydrochloric acid. The product is extracted into ethyl acetate,dried and freed of solvent in vacuo to give 1.85 g. of material which becomes partially 15 crystalline on standing. Trituration with ether gives 1.0 g. (57%) of white crystalline product. Re-crystallization from ethyl acetate (5 ml.) gives 0.85 g. of (trans)-l-(3-mercapto-l-oxopropyl)-3-methylthio-D, L-proline; m.p. 89-93°. <br><br> 20 Anal. Calc'd. for CgHi503N^25 C, 43.35; H, 6.06; <br><br> N, 5.62; S, 25.72 Found: C, 43.35; H, 6.27; N, 5.54; S, 25.91. <br><br> Example 50 <br><br> (trans)-1-(D-3-Mercapto-2-methyl-l-oxopropyl)-3-25 ethylthio-D,L-proline a) (trans)-3-Ethylthio-D,L-proline <br><br> Following the general procedure of Example 4 9 (a) to (d) but substituting an equivalent amount of ethyl mercaptan for the methanethiol one obtains 30 (trans)-3-ethyl-D,L-proline. <br><br> IlAlOQu <br><br> -62- <br><br> 191036 <br><br> b) (trans)-1-[D-3-(Acetylthio)-2-methyl-l-oxopropyl)-3-ethylthio-D,L-proline <br><br> Interaction of the (trans)-2-ethylthio-D,L-proline and D-3-acetylthio-2-methylpropionyl chloride 5 according to the procedure of Example 3 yields <br><br> (trans)-1-[D-3-(acetylthio)-2-methyl-l-oxopropyl]-3-ethylthio-D,L-proline. <br><br> c) (trans)-1-(D-3-Mercapto-2-methyl-l-oxopropyl)-3-ethylthio-D,L-proline <br><br> 10 Hydrolysis of (trans)-1-[D-3-(acetylthio)-2- <br><br> methyl-l-oxopropyl]-3-ethylthio-D,L-proline with an aqueous ammonia solution according to the procedure of Example 4 yields (trans)-1-(D-3-mercapto-2-methyl-l-oxopropyl)-3-ethylthio-D,L-proline. 15 Example 51 <br><br> (trans)-1-(3-Mercapto-l-oxopropyl)-3-phenylthio-D,L-proline <br><br> Following the general procedure of Example 4 9 but substituting an equivalent amount of thiophenol 20 for the methanethiol. yields (trans)-1-(3-mercapto-l-oxopropyl)-3-phenylthio-D,L-proline. <br><br> Example 52 <br><br> (cis)-4-Methoxy-l-(D-3-mercapto-2-trifluoromethyl-1-oxopropyl)-L-proline 25 a) 3-(4-Methoxybenzyl)thio-2-trifluoromethylpro-pionyl chloride <br><br> A neat mixture of 1-trifluoromethylacrylic acid (3.9 g.) and 4-methoxyk.enzylthio (4.3 g.) is stirred at 100-110° for one hour. The mixture is 30 allowed to cool to room temperature and the solid is <br><br> 1 91 <br><br> TT TL 1 f, f&gt; <br><br> U JU <br><br> -63- <br><br> recrystallized from cyclohexane to yield 3-(4-methoxybenzyl)thio-2-trifluoromethylpropanoic acid, m.p. 72-74°. <br><br> Treatment of this acid with thionyl chloride yields 3-(4-methoxybenzyl)thio-2-trifluoromethylpro-pionyl chloride. <br><br> b) (cis)-4-Methoxy-l-[D-3-(4-methoxybenzyl)thio-2-trifluoromethyl-1-oxopropyl]-L-proline <br><br> The 3-(4-methoxybenzyl)thio-2-trifluoromethyl-propionyl chloride is reacted with (cis)-4-methoxy-L-proline to yield (cis)-4-methoxy-l-[D-3-(4-methoxybenzyl )thio-2-trifluoromethyl-l-oxopropyl]-L-proline. <br><br> c) (cis)-4-Methoxy-l-(D-3-mercapto-2-trifluoromethyl- <br><br> 1-oxopropyl)-L-proline <br><br> The (cis)-4-methoxy-l- [D-3- (4-methoxybenzyl)thio <br><br> 2-trifluoromethyl-l-oxopropyl]-L-proline is mixed with trifluoroacetic acid and anisole and stirred under nitrogen. The solvents are removed under vacuum to yield as a residue (cis)-4-methoxy-l-(D-3-mercapto-2-trifluoromethyl-l-oxopropyl)-L-proline. <br><br> Example 53 <br><br> (trans)-4-Methoxy-l-(D-3-mercapto-2-trifluoromethyl-l-oxopropyl)-L-proline <br><br> Following the procedure of Example 52 but substituting (trans)-4-methoxy-L-proline for the cis isomer one obtains (trans)-4-methoxy-l-(D-3-mercapto-2-trifluoromethyl-l-oxopropyl)-L-proline. <br><br> - 64 - <br><br> 4IAlG9a <br><br> Example 54 <br><br> (trans)-4-Ethoxy-l-(D-3-mercapto-2-trifluoromethyl-l-oxopropyl) -L-proline a) 3—Acetylthio-2-trifluoromethylpropionyl chloride <br><br> A mixture of thiolacetic acid and 2-(tri-fluoromethyl)acrylic acid is heated on a steam bath for one hour and then stored at room temperature for 18 hours. The reaction mixture is distilled in vacuo to give 3-acetylthio-2-trifluoromethylpropanoic acid. <br><br> Treatment of this acid with thionyl chloride yields 3-acetylthio-2-trifluoromethylpropionyl chloride b) (trans)-4-Ethoxy-l-[D-3-(acetylthio)-2-trifluoro methyl-l-oxopropy1]-L-proline <br><br> Reacting 3-acetylthio-2-trifluoromethylpropionyl chloride with trans-4-ethoxy-L-proline according to the procedure of Example 3 yields (trans)-4-ethoxy-l-[D-3-(acetylthio)-2-trifluoromethyl-l-oxopropyl]-L-proline. <br><br> c) (trans)-4-Ethoxy-l-(D-3-mercapto-2-trifluoromethyl- <br><br> 1-oxopropyl)-L-proline <br><br> Treating (trans)-4-ethoxy-l- [D-3-(acetylthio)- <br><br> 2-trifluoromethyl-l-oxopropyl]-L-proline with an aqueous solution of ammonia according to the procedure of Example 4 yields (trans)-4-ethoxy-l-(D-3-mercapto-2-trifluoromethyl-l-oxopropyl)-L-proline. <br><br> 191036 <br><br> *-HA169d <br><br> -6 5- <br><br> Example 55 <br><br> 1000 tablets each containing 100 mg. of 1-(D-3-mercapto-l-oxopropyl)-trans-4-methoxy-L-proline, sodium salt, are produced from the following 5 ingredients: <br><br> 1-(3-mercapto-l-oxopropyl)-trans-4-methoxy-L-proline, sodium salt 100 g. <br><br> Corn starch 50 g. <br><br> Gelatin 7.5 g. <br><br> 10 Avicel (microcrystalline cellulose) 25 g. <br><br> Magnesium stearate 2.5 g. <br><br> The 1-(D-3-mercapto-l-oxopropyl)-trans-4-methoxy-L-proline salt and corn starch are admixed with an aqueous solution of the gelatin. The mixture <br><br> 15 is dried and ground to a fine powder. The Avicel and then the magnesium stearate are admixed with the granulation. This is then compressed in a tablet press to form 1000 tablets each containing 100 mg. of active ingredient. <br><br> 20 Example 56 <br><br> Tablets each containing 200 mg. of 1-(D-3-mer-capto-2-methyl-l-oxopropyl)-trans-4-methoxy-L-proline are produced as described in Example 55. <br><br> Example 57 <br><br> 25 1000 tablets each containing 200 mg. of <br><br> 1-(D-3-mercapto-2-methyl-l-oxopropyl)-cis-4-methoxy-L-proline, sodium salt, are produced from the following ingredients: <br><br> 1 <br><br> 91 <br><br> ""6 6- <br><br> 1-(D-3-mercapto-2-methyl-l-oxo- <br><br> propyl)-cis-4-methoxy-L-proline, <br><br> sodium salt 50 g. <br><br> Lactose 25 g. <br><br> 5 Avicel 38 g. <br><br> Corn starch 15 g. <br><br> Magnesium stearate 2 g. <br><br> The 1- (D-3-mercapto-2-methyl-l-oxopropyl)-cis-4-methoxy-L-proline, sodium salt, lactose and Avicel 10 are admixed, then blended with the corn starch. <br><br> , Magnesium stearate is added. The dry mixture is compressed in a tablet press to form 1000 130 mg. tablets each containing 50 mg. of active ingredient. The tablets are coated with a solution of Methocel E 15 15 (methyl cellulose) including as a color a lake containing yellow #6. <br><br> Example 58 <br><br> Two piece #1 gelatin capsules each containing 100 mg. of 1-(D-3-mercapto-2-methyl-l-oxopropyl)-20 cis-4-methoxy-L-proline, sodium salt, are filled with a mixture of the following ingredients: 1-(D-3-mercapto-2-methyl-l-oxo-propyl)-cis-4-methoxy-L- <br><br> proline, sodium salt 100 mg. <br><br> 25 Magnesium stearate 7 mg. <br><br> USP Lactose 193 mg. <br><br></p> </div>

Claims (47)

<div class="application article clearfix printTableText" id="claims"> <p lang="en"> 1 91<br><br> -IIAlOOa<br><br> -6 7-<br><br> Example 59<br><br> An injectable solution is produced as follows:<br><br> (trans)-4-methoxy-l-<br><br> (D-3-mercapto-2-<br><br> methy1-1-oxopropyl)<br><br> -L-proline<br><br> 500<br><br> g-<br><br> Methyl paraben<br><br> 5<br><br> g-<br><br> Propyl paraben<br><br> 1<br><br> g.<br><br> Sodium chloride<br><br> 25<br><br> g-<br><br> Water for injection qs.<br><br> 5<br><br> l<br><br> The active substance, preservatives and sodium chloride are dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into pre-sterilized vials which are then closed with presterilized rubber closures. Each vial contains 5 ml. of solution in a concentration of 100 mg. of active ingredient per ml. of solution for injection.<br><br> The products of each example can be similarly formulated as in Examples 55-59.<br><br> 191036<br><br> IIAlGQa<br><br> -68-<br><br> WHAT/l/WE CLAIM IS:<br><br> ■What iJJ claimed is:<br><br>
1. A compound of the formula<br><br>
X-l^<br><br>
r., r0 h_c<br><br>
I I I<br><br>
r.-s-(ch) ch — co — n c r— coor<br><br>
** n I *<br><br>
h and basic salts thereof wherein the X-R^ group is located at the 3- or 4- position of the proline ring;<br><br>
X is oxygen or sulfur;<br><br>
R is hydrogen or lower alkyl;<br><br>
R^ is lower alkyl, lower alkenyl, lower alkynyl, phenyl, substituted phenyl, pnenyl-lpwer alkylene, or substituted phenyl-lower alkylene;<br><br>
R2 and R^ are independently selected from hydrogen, lower alkyl and trifluoromethyl;<br><br>
0<br><br>
R4 is hydrogen, l!, or r -c-<br><br>
x-R2<br><br>
R3 R2 H2C"°^<br><br>
I I2 I I<br><br>
-s- (ch)— ch- co— n c c00r n |*<br><br>
h<br><br>
R^ is lower alkyl, phenyl, or phenyl-lower alkylene; and n is 0, 1 or 2.<br><br>
1 9<br><br>
4—<br><br>
-69-<br><br>
2. The compound of Claim 1 wherein X is oxygen.<br><br>
3. The compound of Claim 1 wherein X is sulfur.<br><br>
4. The compound of Claim 1 wherein is hydrogen.<br><br>
5. The compound of Claim 1 wherein the proline ring is in the L-configuration.<br><br>
6. A compound of the formula f-Ri<br><br>
R3 R2<br><br>
I I<br><br>
R4"S- (CH)^ CH — CO I COOR<br><br>
H<br><br>
and basic salts thereof wherein the X-R^ group is located at the 3- or 4- position of the proline ring; X is oxygen or sulfur;<br><br>
R is hydrogen;<br><br>
R^ is lower alkyl of 1 to 3 carbons or<br><br>
r2 is hydrogen, methyl or trifluoromethyl; R^ is hydrogen;<br><br>
R^ is hydrogen, acetyl or benzoyl;<br><br>
Rg is hydrogen, methyl, methoxy, methylthio, chloro, fluoro, trifluoromethyl or hydroxy; n is zero or one; and p is zero, one or two.<br><br>
-70-<br><br>
1 91<br><br>
7. The compound of Claim 6 wherein X is oxygen.<br><br>
8. The compound of Claim 7 wherein R^ is hydrogen; R^ is hydrogen or methyl; and n is one.<br><br>
9. The compound of Claim 8 wherein R^ is lower alkyl of 1 to 3 carbons.<br><br>
10. The compound of Claim 9 wherein the proline ring is in the L-configuration; when R^ is other than hydrogen the asymmetric carbon to which R^ is attached is in the D-configuration; and -0-R^ group is at the 4-position of the proline ring and in the cis configuration.<br><br>
11. The compound of Claim 10 wherein R^ is methyl.<br><br>
12. The compound of Claim 11, (cis)-4-methoxy-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline.<br><br>
13. The compound of Claim 11, (cis)-4-methoxy-1-(3-mercapto-l-oxopropyl)-L-proline.<br><br>
14. The compound of Claim 9 wherein the proline ring is in the L-conf iguration; when -*-s °ther than hydrogen the asymmetric carbon to which R2 is attached is in the D-configuration; and the -O-R^ group is at the 4-position of the proline ring and in the trans configuration.<br><br>
15. The compound of Claim 14 wherein R^ is methyl.<br><br>
16. The compound of Claim 15, (trans)-4-methoxy-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline.<br><br>
17. The compound of Claim 15, trans-4-methoxy-1- (3-mercapto-l-oxopropyl)-L-proline.<br><br>
-71-<br><br>
18. The compound of Claim 14 wherein is ethyl.<br><br>
19. The compound of Claim 18, (trans)-4-ethoxy-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline.<br><br>
20. The compound of Claim 14 wherein is n-propyl.<br><br>
21. The compound of Claim 20, (trans)-4-propoxy-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline.<br><br>
22. The compound of Claim 8 wherein R^ is<br><br>
-(CI^) —\C3y ' R6 hydrogen, methyl, methoxy,<br><br>
Wr6<br><br>
methylthio, chloro, fluoro, trifluoromethyl or hydroxy; and p is zero, one or two.<br><br>
23. The compound of Claim 22 wherein the proline ring is in the L-configuration; when is other than hydrogen the asymmetric carbon to which is attached is in the D-configuration; and the -O-R^ group is at the 4-position of the proline ring.<br><br>
24. The compound of Claim 23, (cis)-4-(4-fluorophenoxy)-1-(D-3-mercapto-2-methyl-l-oxopropyl ) -L-proline.<br><br>
25. The compound of Claim 6 wherein X is sulfur.<br><br>
26. The compound of Claim 25 wherein R^ is hydrogen; R^ is hydrogen or methyl; and n is one.<br><br>
27. The compound of Claim 26 wherein R^ is lower alkyl of 1 to 3 carbons.<br><br>
28. The compound of Claim 27 wherein R^ is methyl.<br><br>
-72-<br><br>
191036<br><br>
29. The compound of Claim 28, (trans)-l-(3-mercapto-l-oxopropyl)-3-methy1thio-D,L-proline.<br><br>
methylthio, chloro, fluoro, trifluoromethyl or hydroxy; and p is zero, one or two.<br><br>
31. The compound of Claim 30, 1-(D-3-mercapto-2-methyl-l-oxopropyl)-cis-4-phenylthio-L^proline.<br><br>
acetyl; is hydrogen or methyl; and n is one.<br><br>
33. The compound of Claim 32 wherein is lower alkyl of 1 to 3 carbons.<br><br>
34. The compound of Claim 33 wherein the proline ring is in the L-configuration; when is other than hydrogen the asymmetric carbon to which R^ is attached is in the D-configuration; and -O-R^ group is at the 4-position of the proline ring and in the cis configuration.<br><br>
35. The compound of Claim 34 wherein R^ is methyl.<br><br>
36. The compound of Claim 35, (cis)-4-methoxy-1-[D-(acetylthio)-2-methyl-l-oxopropyl]-L-proline.<br><br>
37. The compound of Claim 33 wherein the proline ring is in the L-configuration; when R^ is other than hydrogen the asymmetric carbon to which R2 is attached is in the D-configuration; and the -O-R^ group is at the 4-position of the proline ring and in the trans configuration.<br><br>
30. The compound of Claim 26 wherein R^ is<br><br>
; R,. is hydrogen, methyl, methoxy,<br><br>
D<br><br>
32. The compound of Claim 7 wherein R^ is<br><br>
-73-<br><br>
JMrBa<br><br>
191036<br><br>
38. The compound of Claim 37 wherein R^ is methyl. ethyl.<br><br>
39. The compound of Claim 37 wherein R^ is<br><br>
40. The compound of Claim 37 wherein R^ is n-propyl.<br><br>
41. The compound of Claim 32 wherein R^ is<br><br>
- (CH_)—(()&gt; ; R,- is hydrogen, methyl, methoxy,<br><br>
2 p vr&gt;R 6<br><br>
6<br><br>
methylthio, chloro, fluoro, trifluoromethyl or hydroxy; and p is zero, one or two.<br><br>
42. The compound of Claim 25 wherein R^ is acetyl; R2 is hydrogen or methyl; and n is one.<br><br>
4 3. The compound of Claim 4 2 wherein R^ is lower alkyl of 1 to 3 carbons.<br><br>
44. The compound of Claim 4 2 wherein R^ is<br><br>
~(CVp~(C^R ; R6 is hydroc?en, methyl, methoxy,<br><br>
methylthio, chloro, fluoro, trifluoromethyl or hydroxy; and p is zero, one or two.<br><br>
45. A composition comprising an effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier therefor.<br><br>
. P. &amp; S.
46. A method for reducing blood pressure in vim huwM<br><br>
hypertensive^mammals which comprises administering an effective amount of the composition of Claim 45.<br><br>
^ 1910 3 6<br><br>
^ .. Hfll6 9a<br><br>
-74-<br><br>
47. A process for preparing a compound of the formula<br><br>
X-R<br><br>
R3 E2 H2C '^1<br><br>
I I I<br><br>
R.-S- (CH) CH — CO — N C r— COOR<br><br>
i n I *<br><br>
H<br><br>
and basic salts thereof wherein the X-R^ group is located at the 3- or 4- position of the proline ring;<br><br>
X is oxygen or sulfur;<br><br>
R is hydrogen or lower alkyl;<br><br>
R^ is lower alkyl, lower alkenyl, lower alkynyl, phenyl, substituted phenyl, phenyl-lower alkylene, or substituted phenyl-lower alkylene;<br><br>
R2 and R^ are independently selected from hydrogen, lower alkyl and trifluoromethyl;<br><br>
R4 is hydrogen, _Ji,_ or<br><br>
5<br><br>
X-Rx<br><br>
R R HC'^3-<br><br>
I3 I2 2i<br><br>
-S- (CH)— CH- CO— N C COOR<br><br>
n |*<br><br>
H<br><br>
Rj. is lower alkyl, phenyl, or phenyl-lower alkylene; and n is 0, 1 or 2f characterized by coupling a proline compound of the formula<br><br>
XR,<br><br>
,^&gt;&lt; 1<br><br>
'1—<br><br>
H 2C<br><br>
COOR<br><br>
H<br><br>
1910<br><br>
HA169&amp;-<br><br>
-75-<br><br>
.1 ?&amp;.<br><br>
with an acid er ifeo ehcmioal equivalent, of the formula<br><br>
R4<br><br>
I'<br><br>
(CH)<br><br>
n<br><br>
2<br><br>
CH-<br><br>
-COOH<br><br>
wherein is hydrogen or R^-CO- to form a product wherein R^ is hydrogen or R^CO, and if desired, hydrolyzing said product wherein R^ is R^CO to form the product wherein R^ is hydrogen and if desired oxidizing a product wherein R^ is hydrogen with iodine to form the product wherein R4 is<br><br>
*3<br><br>
I<br><br>
(CH)<br><br>
2<br><br>
CH-<br><br>
X-R,<br><br>
-S (CH) CH CO' N V* COOR<br><br>
lX<br><br>
H<br><br>
48. A process according to claim wherein a compound of the formula<br><br>
H2c<br><br>
Htl<br><br>
"R1<br><br>
COOR<br><br>
H<br><br>
is reacted with an acid or ito chemical e.quwalonfa of the formula<br><br>
R4'<br><br>
3<br><br>
(CH)<br><br>
n<br><br>
R„<br><br>
I2<br><br>
-CH-<br><br>
-COOH<br><br>
to form a product wherein R^ is hydrogen or R^-CO.<br><br>
49. A process according to claim ^wherein a compound of the formula<br><br>
R5CO-<br><br>
R3<br><br>
(CH)<br><br>
n<br><br>
R2<br><br>
-CH-<br><br>
H2 -CO N<br><br>
XR,<br><br>
-COOR<br><br>
H<br><br>
\<br><br>
19103<br><br>
■ HA169a—<br><br>
,.fc ' -76-<br><br>
is hydrolyzed to form a product wherein R. is hydrogen.<br><br>
4-7<br><br>
50. A process according to claimwherein a product wherein R^ is hydrogen is oxidized with iodine to form a product wherein R^ is<br><br>
R„ R, X"R^<br><br>
3<br><br>
2<br><br>
-S (CH) CH—CO N-<br><br>
-CO0R<br><br>
A.J. P.&amp;S. D n<br><br>
&lt;3.^ or&gt;e of- ^<br><br>
The Process of/claims 47-50 wherein X is<br><br>
A J. P. &amp; S. oxygen. D<br><br>
Q.A.M Of\t o-jf fit _ 52. The process of/claims 47-50 wherein X is sulfur,<br><br>
1^/3-7 of a"T"p"&amp;'S T Process of ^claims 47-4 9 wherein R^ is hydrogen. ^ n<br><br>
J A. o. °f<br><br>
54. The process of/claims 47-50 wherein the proline<br><br>
A • ^ S. ring is in the L-conf iguration. o<br><br>
' ^ "" " ' ^ OA.M C&gt;fM° of<br><br>
55. A process according to /claims 47-49 wherein the product is of the formula<br><br>
IJIIJZL.<br><br>
*3 *2<br><br>
I I<br><br>
R4-S- (CH) ^ CH — CO N -C*~ COOR<br><br>
and basic salts thereof wherein the X-R^ group is located at the 3- or 4- position of the proline ring; X is oxygen or sulfur;<br><br>
R is hydrogen;<br><br>
R^ is lower alkyl of 1 to 3 carbons or<br><br>
R2 is hydrogen, methyl or trifluoromethyl;<br><br>
R^ is hydrogen;<br><br>
R^ is hydrogen, acetyl or benzoyl;<br><br>
R, is hydrogen, methyl, methoxy, methylthio,<br><br>
D<br><br>
chloro, fluoro, trifluoromethyl or hydroxy; n is zero or one; and p is zero, one or two.<br><br>
191036<br><br>
-77-<br><br>
56. The process of claim 55 wherein X is oxygen.<br><br>
57. The process of claim 56 wherein is hydrogen; R^ is hydrogen or methyl; and n is one.<br><br>
58. The process of claim 57 wherein R^ is lower alkyl of 1 to 3 carbons.<br><br>
59. The process of claim 58 wherein the proline ring is in the L-configuration; when R2 is other than hydrogen the asymmetric carbon to which R2 is attached is in the D-configuration; and -O-R^ group is at the 4-position of the proline ring and in the cis configuration.<br><br>
60. The process of claim 59 wherein R1 is methyl.<br><br>
61. The process of claim 60 wherein the product is (cis)-4-methoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline.<br><br>
62. The process of claim 60 wherein the product is (cis)-4^-methoxy-l-(3-mercapto-l-oxopropyl)-L-proline.<br><br>
63. The process of claim 58 wherein the proline ring is in the L-configuration; when R2 is other than hydrogen the asymmetric carbon to which R2 is attached is in the D-configuration; and the -O-R^ group is at the 4-position of the proline ring and in the trans configuration.<br><br>
64. The process of claim 63 wherein R^ is methyl.<br><br>
65. The process of claim 64 wherein the product is (trans)-4-methoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline,<br><br>
66. The process of claim 64 wherein the product is trans-4-methoxy-l-(3-mercapto-l-oxopropyl-L-proline.<br><br>
67. The process of claim 63 wherein R^ is ethyl.<br><br>
68. The process of claim 67 wherein the product is (trans)-4-ethoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline.<br><br>
1910 3<br><br>
* HAl 6 9 ci<br><br>
-78-<br><br>
69. The process of claim 63 wherein is n-propyl.<br><br>
70. The process of claim 69 wherein the product is (trans)-4-propoxy-l-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline.<br><br>
71. The process of claim 57 wherein R^ is<br><br>
-(CH2)p—; Rg is hydrogen, methyl, methoxy, methylthio, chloro, fluoro, trifluoromethyl or hydroxy;<br><br>
and p is zero, one or two,<br><br>
72. The process of claim 71 wherein the proline ring is in the L-configuration; when R2 is other than hydrogen the asymmetric carbon to which R2 is attached is in the D-configuration; and the -O-R^ group is at the 4-position of the proline ring.<br><br>
73. The process of claim 72 wherein the product is (cis)-4-(4-fluorophenoxy)-1-(D-3-mercapto-2-methyl-l-oxopropyl)-L-proline.<br><br>
74. The process of claim 55 wherein X is suflur.<br><br>
75. The process of claim 74 wherein R4 is hydrogen; R2 is hydrogen or methyl; and n is one.<br><br>
76. The process of claim 75 wherein R^ is lower alkyl of 1 to 3 carbons.<br><br>
77. The process of claim 76 wherein R^ is methyl.<br><br>
78. The process of claim 77 wherein the product is (trans)-1-(3-mercapto-l-oxopropyl)^3-methylthio-D,L-proline.<br><br>
79. The process of claim 75 wherein R1 is<br><br>
- (CH2)p—&lt;0^ J Rg is hydrogen, methyl, methoxy,<br><br>
methylthio, chloro, fluoro, trifluoromethyl or hydroxy;<br><br>
and p is zero, one or two.<br><br>
4<br><br>
1 91 C 3 6<br><br>
-Tmruva=^<br><br>
-79-<br><br>
80. The process of claim 79 wherein the product is 1-(D-3-mercapto-2-methyl-l-oxopropyl)-cis-4-phenylthio-L-proline.<br><br>
81. The process of claim 56 wherein R4 is acetyl; R2 is hydrogen or methyl; and n is one,<br><br>
82. The process of claim 81 wherein R^ is lower alkyl of 1 to 3 carbons.<br><br>
83. The process of claim 82 wherein the proline ring is in the L-configuration; when R2 is other than hydrogen the asymmetric carbon to which R2 is attached is in the D-configuration; and -0-R^ group is at the 4-position of the proline ring and in the cis configuration,<br><br>
84. The process of claim 83 wherein R^ is methyl.<br><br>
85. The process of claim 84 wherein the product is (cis)-4-methoxy-l-[D-(acetylthio)-2-methyl-l-oxo-propyl] -L-proline.<br><br>
A. J* P* ^ 86, The process of claim wherein the proline<br><br>
J ring is in the L-conf iguration; when R2 is other than hydrogen the asymmetric carbon to which R2 is attached<br><br>
^ J P. &amp;-$. in the D-conf iguration; and the -O-R^ group is at the r\ 4-position of the proline ring and in the trans configuration,<br><br>
87, The process of claim 86 wherein R1 is methyl.<br><br>
88, The process of claim 86 wherein R^ is ethyl.<br><br>
89, The process of claim 86 wherein R^ is n-propyl.<br><br>
90, The process of claim 81 wherein R^ is<br><br>
-(CH-) ——(O-v ' is hydrogen, methyl, methoxy, 1 P V_7^r6 b methylthio, chloro, fluoro, trifluoromethyl or hydroxy; and p is zero, one or two.<br><br>
wm -wr.<br><br>
1 0 3 6<br><br>
-80-<br><br>
91. The process of claim 74 wherein R4 is acetyl; R£ is hydrogen or methyl; and n is one.<br><br>
92. The process of claim 91 wherein R^ is lower alkyl of 1 to 3 carbons.<br><br>
93. The process of claim 91 wherein R^ is<br><br>
(CH„) —; Rc is hydrogen, methyl, methoxy,<br><br>
2 p \—T^Rg o methylthio, chloro, fluoro&gt; trifluoromethyl or hydroxy;<br><br>
and p is zero, one or two,<br><br>
A.J. P. &amp; S. 94. A compound as claimed in any one of claims ii —i t-, 1 to 44 substantially as hereinbefore described with<br><br>
Per.A.i;.J....'«n. r i i reference to any of feho Gitnmplca i \ — Z&gt;H-<br><br>
J. P. &amp; S. 95. A composition substantially as hereinbefore described with reference to any of tho ok ample, a i<br><br>
^ process as claimed in any one of claims<br><br>
47 to 93 when performed substantially as hereinbefore described, ^ de-pi/^J) IrC cJcu.**- 1 pr&amp;pcxred L<br><br>
A J P 8t S 97. A proauot of^a process as claimed in any q one of claims 47 to 9 3 and 96.<br><br>
J tl 1 '&amp;!<br><br>
DATED THIS HHv. DAY OF l9^<br><br>
A, J. PARK &amp; SON<br><br>
PR ^ £sul£<br><br>
■ -•:.&gt;VT*PC'* TV.?. ArW.AM"!<br><br>
</p>
</div>
NZ191036A 1978-08-11 1979-07-17 Ether and thioether mercaptoacyl prolines and pharmaceutical compositions NZ191036A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93288378A 1978-08-11 1978-08-11
KR1019790002731A KR830002450B1 (en) 1978-08-11 1979-08-10 Method for preparing mercaptoacyl derivative of substituted proline

Publications (1)

Publication Number Publication Date
NZ191036A true NZ191036A (en) 1984-05-31

Family

ID=26626596

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ191036A NZ191036A (en) 1978-08-11 1979-07-17 Ether and thioether mercaptoacyl prolines and pharmaceutical compositions

Country Status (30)

Country Link
JP (2) JPS5527199A (en)
KR (1) KR830002450B1 (en)
AR (1) AR229081A1 (en)
AT (1) AT379589B (en)
AU (1) AU530690B2 (en)
BE (1) BE878191A (en)
CA (1) CA1144930A (en)
CH (1) CH642064A5 (en)
CS (1) CS228118B2 (en)
DD (1) DD145749A5 (en)
DE (1) DE2932021C2 (en)
DK (1) DK154553C (en)
ES (1) ES483311A1 (en)
FI (1) FI69834C (en)
FR (1) FR2435469A1 (en)
GB (1) GB2028327B (en)
GR (1) GR72420B (en)
IE (1) IE48802B1 (en)
IN (1) IN152712B (en)
IT (1) IT1117782B (en)
LU (2) LU81593A1 (en)
NL (2) NL193374C (en)
NZ (1) NZ191036A (en)
PH (1) PH15030A (en)
PT (1) PT70049A (en)
RO (1) RO78870B (en)
SE (1) SE447477B (en)
SU (1) SU1066460A3 (en)
YU (1) YU41876B (en)
ZA (1) ZA793633B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483861A (en) * 1978-10-31 1984-11-20 Santen Pharmaceutical Co., Ltd. Antihypertensive sulfur-containing compounds
CA1132985A (en) * 1978-12-22 1982-10-05 John Krapcho Ketal and thioketal derivatives of mercaptoacyl prolines
US4347371A (en) * 1978-12-30 1982-08-31 Santen Pharmaceutical Co., Ltd. Disulfide compounds
US4234489A (en) * 1979-06-25 1980-11-18 E. R. Squibb & Sons, Inc. Pyroglutamic acid derivatives and analogs
US4288368A (en) * 1979-07-30 1981-09-08 E. R. Squibb & Sons, Inc. Dithioacylproline derivatives
US4291040A (en) * 1979-10-22 1981-09-22 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of 4-disubstituted prolines and 4-substituted dehydroprolines
US4692458A (en) * 1980-03-05 1987-09-08 University Of Miami Anti-hypertensive agents
AU542211B2 (en) * 1980-03-07 1985-02-14 Gruppo Lepetit S.P.A. Mercaptocycloalkyl carbonyl prolines
SE431331B (en) * 1980-03-21 1984-01-30 Squibb & Sons Inc NEW THERAPEUTICALLY ACTIVE SULFUR CONTAINING N-ACYLATED DERIVATIVES OF 4-OXO-L-PROLINE
US4284624A (en) 1980-05-02 1981-08-18 E. R. Squibb & Sons, Inc. Mixed disulfides
US4390695A (en) * 1980-06-23 1983-06-28 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4578474A (en) * 1980-06-23 1986-03-25 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4316905A (en) * 1980-07-01 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of various 4-substituted prolines
US4332726A (en) * 1980-08-25 1982-06-01 E. R. Squibb & Sons, Inc. Purification of mercaptoacyl amino acids
US4307110A (en) * 1980-09-12 1981-12-22 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of 3-substituted proline derivatives
US4311705A (en) * 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
US4312809A (en) 1980-10-31 1982-01-26 E. R. Squibb & Sons, Inc. Lactam derivatives of mercaptoacylamino acids
US4462943A (en) * 1980-11-24 1984-07-31 E. R. Squibb & Sons, Inc. Carboxyalkyl amino acid derivatives of various substituted prolines
US4384123A (en) * 1980-12-04 1983-05-17 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4374131A (en) 1981-04-27 1983-02-15 E. R. Squibb & Sons, Inc. Amino and substituted amino phosphinyl-alkanoyl compounds
US4416831A (en) 1981-04-27 1983-11-22 E. R. Squibb & Sons, Inc. Amino and substituted amino phosphinylalkanoyl compounds
US4381297A (en) 1981-05-04 1983-04-26 E. R. Squibb & Sons, Inc. Substituted carbonyl phosphinyl-alkanoyl compounds
US4416833A (en) 1981-05-04 1983-11-22 E. R. Squibb & Sons, Inc. Substituted carbonyl phosphinyl-alkanoyl compounds
US4497953A (en) * 1981-06-01 1985-02-05 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4377701A (en) * 1981-09-21 1983-03-22 E. R. Squibb & Sons, Inc. 4-Methylene-1-[[(alranoyl or arylcarbonyl)mercapto]acyl]proline and pipecolic acid
US4555506A (en) * 1981-12-24 1985-11-26 E. R. Squibb & Sons, Inc. Phosphorus containing compounds and use as hypotensives
US4452791A (en) * 1982-03-15 1984-06-05 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4560680A (en) * 1982-03-15 1985-12-24 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4616005A (en) * 1982-06-23 1986-10-07 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4703043A (en) * 1982-06-23 1987-10-27 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive
US4452790A (en) * 1982-06-23 1984-06-05 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4567166A (en) * 1982-07-14 1986-01-28 E. R. Squibb & Sons, Inc. Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension
EP0187037A3 (en) * 1984-12-21 1988-03-23 Takeda Chemical Industries, Ltd. Piperidine derivatives, their production and use
CA2021409A1 (en) * 1989-08-21 1991-02-22 Donald S. Karanewsky Phosphonate substituted amino or imino acids useful as antihypertensives
JPH05344844A (en) * 1992-06-12 1993-12-27 Suzumo Kiko Kk Method for producing roasted rice ball cracker
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
US5435286A (en) * 1994-05-02 1995-07-25 Cummins Engine Company, Inc. Ball link assembly for vehicle engine drive trains
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
WO2006038119A1 (en) * 2004-10-08 2006-04-13 Warner-Lambert Company Llc Stereoselective synthesis of n-protected alkoxy prolines
GB0715626D0 (en) 2007-08-10 2007-09-19 Generics Uk Ltd Crystalline form of zofenopril calcium
US8853421B2 (en) 2008-02-27 2014-10-07 Generics [Uk] Limited Crystalline forms of zofenopril calcium
JP5530369B2 (en) * 2008-02-27 2014-06-25 ジェネリクス・[ユーケー]・リミテッド New crystal form
SI23949A (en) 2011-12-19 2013-06-28 Silverstone Pharma The new crystalline salts of zofenopril, the procedure for obtaining them and their use in therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340092A2 (en) * 1976-02-09 1977-09-02 Roussel Uclaf Analgesic (N)-thiazolyl-quinoline carboxamides - prepd. from the corresp. quinoline carboxylic acid and (2)-amino-thiazole
AU509899B2 (en) * 1976-02-13 1980-05-29 E.R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4116962A (en) * 1976-12-03 1978-09-26 E. R. Squibb & Sons, Inc. Pyrrolidine and piperidine-2-carboxylic acid derivatives
US4113715A (en) * 1977-01-17 1978-09-12 E. R. Squibb & Sons, Inc. Amino acid derivatives
US4108886A (en) * 1977-03-11 1978-08-22 E. R. Squibb & Sons, Inc. Thiopropanoylamino acid derivatives
PH15381A (en) * 1978-02-21 1982-12-17 Squibb & Sons Inc Halogen substituted mercaptoacylamino acids
US4154934A (en) * 1978-08-11 1979-05-15 E. R. Squibb & Sons, Inc. Mercaptoacylamino derivatives of heterocyclic carboxylic acids

Also Published As

Publication number Publication date
AR229081A1 (en) 1983-06-15
DK335879A (en) 1980-02-12
DK154553C (en) 1989-04-17
RO78870A (en) 1982-07-06
KR830002450B1 (en) 1983-10-26
NL7906120A (en) 1980-02-13
SE7906722L (en) 1980-02-12
SE447477B (en) 1986-11-17
NL990024I1 (en) 1999-11-01
YU192379A (en) 1983-02-28
JPH0134987B2 (en) 1989-07-21
FI792498A (en) 1980-02-12
CS228118B2 (en) 1984-05-14
JPH01287069A (en) 1989-11-17
GB2028327A (en) 1980-03-05
PT70049A (en) 1979-09-01
NL193374B (en) 1999-04-01
ATA541679A (en) 1985-06-15
NL193374C (en) 1999-08-03
FI69834B (en) 1985-12-31
KR830001269A (en) 1983-04-29
RO78870B (en) 1985-01-30
LU90403I2 (en) 2000-07-07
ZA793633B (en) 1980-07-30
DE2932021C2 (en) 1994-05-19
IT7949954A0 (en) 1979-08-03
JPS5527199A (en) 1980-02-27
GR72420B (en) 1983-11-03
CA1144930A (en) 1983-04-19
CH642064A5 (en) 1984-03-30
NL990024I2 (en) 1999-11-01
AT379589B (en) 1986-01-27
DE2932021A1 (en) 1980-02-21
FI69834C (en) 1986-05-26
AU4919079A (en) 1980-02-14
PH15030A (en) 1982-05-13
SU1066460A3 (en) 1984-01-07
FR2435469A1 (en) 1980-04-04
DD145749A5 (en) 1981-01-07
FR2435469B1 (en) 1983-02-11
ES483311A1 (en) 1980-04-16
GB2028327B (en) 1982-11-24
DK154553B (en) 1988-11-28
LU81593A1 (en) 1979-12-07
IE48802B1 (en) 1985-05-15
IN152712B (en) 1984-03-17
AU530690B2 (en) 1983-07-28
BE878191A (en) 1980-02-11
IT1117782B (en) 1986-02-24
IE791544L (en) 1980-02-11
YU41876B (en) 1988-02-29

Similar Documents

Publication Publication Date Title
CA1144930A (en) Mercaptoacyl derivatives of substituted prolines
US4316906A (en) Mercaptoacyl derivatives of substituted prolines
US4154840A (en) Antihypertensive pipecolic acid derivatives
US4105776A (en) Proline derivatives and related compounds
CA1124725A (en) Alkanoyl-thio-acyl derivatives of dehydrocyclicimino acids
US4128653A (en) Reduction of blood pressure with carboxyalkylacyl-pipecolic acid derivatives
US4070361A (en) Mercaptoalkylsulfonyl proline and pipecolic acid and esters thereof
GB1576161A (en) Proline derivatives and related compounds
US4692458A (en) Anti-hypertensive agents
US4154937A (en) Hydroxycarbamoylalkylacylpipecolic acid compounds
US4241076A (en) Halogenated substituted mercaptoacylamino acids
CA1124723A (en) Halogen substituted mercaptoacylamino-prolines and pipecolic acids
US4206122A (en) Derivatives of pyrrolidinecarboxaldehyde and piperidinecarboxaldehyde and intermediates therefor
EP0036713B1 (en) Angiotensin converting enzyme inhibitors
US4734420A (en) Anti-hypertensive agents
US4307110A (en) Mercaptoacyl derivatives of 3-substituted proline derivatives
US4690936A (en) Anti-hypertensive agents
US4833152A (en) Anti-hypertensive agents
CA1103255A (en) Proline derivatives and related compounds
CA1103257A (en) Proline derivatives and related compounds
CA1102337A (en) Proline derivatives and related compounds
KR810000056B1 (en) Process for preparing proline derivatives and related compounds
HU179782B (en) Process for preparing ether and thioether derivatives of mercapto-acyl-prolines
GB2039906A (en) Dehydroproline derivative
NL8104049A (en) METHOD FOR PREPARING A THERAPEUTIC PREPARATION, AND METHOD FOR PREPARING SUITABLE COMPOUNDS.